BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17. [PMID: 10331074 DOI: 10.1146/annurev.pharmtox.39.1.1] [Cited by in Crossref: 862] [Cited by in F6Publishing: 772] [Article Influence: 39.2] [Reference Citation Analysis]
Number Citing Articles
1 Castrignanò S, D'Avino S, Di Nardo G, Catucci G, Sadeghi SJ, Gilardi G. Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops. Biochim Biophys Acta Proteins Proteom 2018;1866:116-25. [PMID: 28734977 DOI: 10.1016/j.bbapap.2017.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87-93. [PMID: 17192506 DOI: 10.1177/0091270006295063] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
3 Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother 2017;72:2879-86. [PMID: 28605493 DOI: 10.1093/jac/dkx169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
4 Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N -desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011;41:851-62. [DOI: 10.3109/00498254.2011.590546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Schiavini P, Cheong KJ, Moitessier N, Auclair K. Active Site Crowding of Cytochrome P450 3A4 as a Strategy To Alter Its Selectivity. ChemBioChem 2017;18:248-52. [DOI: 10.1002/cbic.201600546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
6 Lim YP, Ma CY, Liu CL, Lin YH, Hu ML, Chen JJ, Hung DZ, Hsieh WT, Huang JD. Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation. Evid Based Complement Alternat Med 2012;2012:242810. [PMID: 22645625 DOI: 10.1155/2012/242810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
7 Dimaraki EV, Jaffe CA. Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test. The Journal of Clinical Endocrinology & Metabolism 2003;88:3113-6. [DOI: 10.1210/jc.2002-021778] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
8 Drögemöller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Schneider N, Olckers A, Wright G, Warnich L. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 2013;4:17. [PMID: 23423246 DOI: 10.3389/fgene.2013.00017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
9 Delgoda R, Westlake AC. Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol Rev 2004;23:239-49. [PMID: 15898829 DOI: 10.2165/00139709-200423040-00004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
10 Chang TK, Yeung RK. Effect of trans -resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O -dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 2001;79:220-6. [DOI: 10.1139/y00-130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
11 McClary WD, Sumida JP, Scian M, Paço L, Atkins WM. Membrane Fluidity Modulates Thermal Stability and Ligand Binding of Cytochrome P4503A4 in Lipid Nanodiscs. Biochemistry 2016;55:6258-68. [PMID: 27782404 DOI: 10.1021/acs.biochem.6b00715] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
12 Savas U, Griffin KJ, Johnson EF. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. Mol Pharmacol 1999;56:851-7. [PMID: 10531387 DOI: 10.1124/mol.56.5.851] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 3.5] [Reference Citation Analysis]
13 Asha S, Vidyavathi M. Cunninghamella – A microbial model for drug metabolism studies – A review. Biotechnology Advances 2009;27:16-29. [DOI: 10.1016/j.biotechadv.2008.07.005] [Cited by in Crossref: 145] [Cited by in F6Publishing: 117] [Article Influence: 12.1] [Reference Citation Analysis]
14 Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5:243-272. [PMID: 15102541 DOI: 10.1517/phgs.5.3.243.29833] [Cited by in Crossref: 211] [Cited by in F6Publishing: 184] [Article Influence: 12.4] [Reference Citation Analysis]
15 Smith M, Hymery N, Troadec S, Pawtowski A, Coton E, Madec S. Hepatotoxicity of fusariotoxins, alone and in combination, towards the HepaRG human hepatocyte cell line. Food and Chemical Toxicology 2017;109:439-51. [DOI: 10.1016/j.fct.2017.09.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
16 Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, Skiles GL. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 2008;36:2355-70. [PMID: 18669588 DOI: 10.1124/dmd.108.020602] [Cited by in Crossref: 100] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
17 King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003;55:625-9. [PMID: 12814460 DOI: 10.1046/j.1365-2125.2003.01798.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
18 Liu W, Ning R, Chen R, Hu J, Gui H, Wang Y, Liu J, Hu G, Yang J, Guo Q. Gambogic acid suppresses cytochrome P450 3A4 by downregulating pregnane X receptor and up-regulating DEC1 in human hepatoma HepG2 cells. Toxicol Res 2015;4:1059-71. [DOI: 10.1039/c4tx00239c] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Kluth D, Banning A, Paur I, Blomhoff R, Brigelius-flohé R. Modulation of pregnane X receptor-and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radical Biology and Medicine 2007;42:315-25. [DOI: 10.1016/j.freeradbiomed.2006.09.028] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
20 Du Preez I, Loots DT. Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance. Drug Metabolism Reviews 2019;50:466-81. [DOI: 10.1080/03602532.2018.1559184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
21 Wei Z, Jiang S, Zhang Y, Wang X, Peng X, Meng C, Liu Y, Wang H, Guo L, Qin S, He L, Shao F, Zhang L, Xing Q. The effect of microRNAs in the regulation of human CYP3A4: a systematic study using a mathematical model. Sci Rep 2014;4:4283. [PMID: 24594634 DOI: 10.1038/srep04283] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
22 Zhang B, Cheng Q, Ou Z, Lee JH, Xu M, Kochhar U, Ren S, Huang M, Pflug BR, Xie W. Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 2010;151:5721-9. [PMID: 20962047 DOI: 10.1210/en.2010-0708] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
23 Park WS, Jun MA, Shin MS, Kwon SW, Kang SK, Kim KY, Dal Rhee S, Bae MA, Narsaiah B, Lee DH, Cheon HG, Ahn JH, Kim SS. Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors. Journal of Fluorine Chemistry 2009;130:1001-10. [DOI: 10.1016/j.jfluchem.2009.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L, Yang L. Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction. Journal of Ethnopharmacology 2013;150:619-38. [DOI: 10.1016/j.jep.2013.09.018] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
25 Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, Goldfarb PS. Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. Mutat Res 2002;500:103-10. [PMID: 11890939 DOI: 10.1016/s0027-5107(01)00305-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
26 Xia J, Lin J, Zhu S, Du Z, Guo J, Han Z, Li J, Zhang Y. Lycopene protects against atrazine-induced hepatotoxicity through modifications of cytochrome P450 enzyme system in microsomes. Experimental and Toxicologic Pathology 2016;68:223-31. [DOI: 10.1016/j.etp.2015.12.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
27 Sultana H, Kato A, Ohashi A, Takashima R, Katsurai T, Sato S, Monma M, Ohsaki Y, Goto T, Komai M, Shirakawa H. Effect of Vitamin K-Mediated PXR Activation on Drug-Metabolizing Gene Expression in Human Intestinal Carcinoma LS180 Cell Line. Nutrients 2021;13:1709. [PMID: 34069974 DOI: 10.3390/nu13051709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Denisov IG, Baas BJ, Grinkova YV, Sligar SG. Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 2007;282:7066-76. [PMID: 17213193 DOI: 10.1074/jbc.M609589200] [Cited by in Crossref: 153] [Cited by in F6Publishing: 107] [Article Influence: 10.9] [Reference Citation Analysis]
29 Fernandes D, Dimastrogiovanni G, Blázquez M, Porte C. Metabolism of the polycyclic musk galaxolide and its interference with endogenous and xenobiotic metabolizing enzymes in the European sea bass (Dicentrarchus labrax). Environmental Pollution 2013;174:214-21. [DOI: 10.1016/j.envpol.2012.11.033] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
30 Davydov DR, Fernando H, Baas BJ, Sligar SG, Halpert JR. Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry 2005;44:13902-13. [PMID: 16229479 DOI: 10.1021/bi0509346] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
31 Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 2002;34:83-448. [DOI: 10.1081/dmr-120001392] [Cited by in Crossref: 558] [Cited by in F6Publishing: 143] [Article Influence: 29.4] [Reference Citation Analysis]
32 van Waterschoot RAB, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH. Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metab Dispos 2009;37:2305-13. [DOI: 10.1124/dmd.109.029397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
33 Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA, Thurston DE, Tomaszewski JE, Ames MM. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. Cancer Chemother Pharmacol 2011;68:777-86. [PMID: 21188379 DOI: 10.1007/s00280-010-1517-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
34 Denisov IG, Frank DJ, Sligar SG. Cooperative properties of cytochromes P450. Pharmacol Ther 2009;124:151-67. [PMID: 19555717 DOI: 10.1016/j.pharmthera.2009.05.011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
35 Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol 2011;7:1185-200. [PMID: 21899476 DOI: 10.1517/17425255.2011.608660] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
36 Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K. Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone. Drug Metab Dispos 2008;36:2287-91. [DOI: 10.1124/dmd.108.021816] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
37 Kato K, Ohbuchi M, Hamamura S, Ohshita H, Kazuki Y, Oshimura M, Sato K, Nakada N, Kawamura A, Usui T, Kamimura H, Tateno C. Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver. Drug Metab Dispos 2015;43:1208-17. [DOI: 10.1124/dmd.115.063479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
38 Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J, Schuetz E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60:1399-1406. [PMID: 11723248 DOI: 10.1124/mol.60.6.1399] [Cited by in Crossref: 254] [Cited by in F6Publishing: 235] [Article Influence: 12.7] [Reference Citation Analysis]
39 Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 2010;99:486-514. [PMID: 19479982 DOI: 10.1002/jps.21802] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
40 Kawaguchi H, Matsui Y, Watanabe Y, Takakura Y. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse. J Pharmacol Exp Ther 2004;308:91-6. [PMID: 14569074 DOI: 10.1124/jpet.103.057521] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
41 Gawrońska-szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005;61:375-9. [DOI: 10.1007/s00228-005-0901-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
42 Davis JA, Greene RJ, Han S, Rock DA, Wienkers LC. Formation of raloxifene homo-dimer in CYP3A4, evidence for multi-substrate binding in a single catalytically competent P450 active site. Arch Biochem Biophys 2011;513:110-8. [PMID: 21767526 DOI: 10.1016/j.abb.2011.06.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. The Journal of Clinical Pharmacology 2018;58:425-33. [DOI: 10.1002/jcph.1038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Wang Y, Sparidans RW, Potters S, Lebre MC, Beijnen JH, Schinkel AH. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacol Res 2021;172:105850. [PMID: 34450308 DOI: 10.1016/j.phrs.2021.105850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Imai S, Yoshioka Y, Morishita Y, Yoshida T, Uji M, Nagano K, Mukai Y, Kamada H, Tsunoda S, Higashisaka K, Tsutsumi Y. Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro. Nanoscale Res Lett 2014;9:651. [PMID: 25520598 DOI: 10.1186/1556-276X-9-651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
46 Davydov DR, Davydova NY, Tsalkova TN, Halpert JR. Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4. Arch Biochem Biophys 2008;471:134-45. [PMID: 18206979 DOI: 10.1016/j.abb.2008.01.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
47 Schyman P, Usharani D, Wang Y, Shaik S. Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin? J Phys Chem B 2010;114:7078-89. [PMID: 20405876 DOI: 10.1021/jp1008994] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
48 Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama M, Chida K, Watanabe H. Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method. Clin Pharmacol Ther 2013;94:702-8. [DOI: 10.1038/clpt.2013.167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
49 Varma MV, Pang KS, Isoherranen N, Zhao P. Dealing with the complex drug-drug interactions: Towards mechanistic models: Dealing with the Complex Drug-Drug Interactions. Biopharm Drug Dispos 2015;36:71-92. [DOI: 10.1002/bdd.1934] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
50 Chakrapani BP, Kumar S, Subramaniam JR. Development and evaluation of an in vivo assay in Caenorhabditis elegans for screening of compounds for their effect on cytochrome P450 expression. J Biosci 2008;33:269-77. [PMID: 18535361 DOI: 10.1007/s12038-008-0044-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
51 Shi Y, Liu Y, Wei Z, Zhang Y, Zhang L, Jiang S, Xiong Y, Shen L, He L, Xing Q, Qin S. Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population. Pharmacogenomics 2015;16:1379-86. [DOI: 10.2217/pgs.15.82] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
52 Granvil CP, Yu A, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam. Drug Metab Dispos 2003;31:548-58. [DOI: 10.1124/dmd.31.5.548] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 4.8] [Reference Citation Analysis]
53 Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 2011;163:937-47. [PMID: 21323901 DOI: 10.1111/j.1476-5381.2011.01270.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 7.8] [Reference Citation Analysis]
54 Liu FJ, Song X, Yang D, Deng R, Yan B. The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 2008;409:243-50. [PMID: 17764444 DOI: 10.1042/BJ20070613] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
55 Gay SC, Roberts AG, Halpert JR. Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem 2010;2:1451-68. [PMID: 21103389 DOI: 10.4155/fmc.10.229] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
56 Shaik S, Kumar D, de Visser SP, Altun A, Thiel W. Theoretical Perspective on the Structure and Mechanism of Cytochrome P450 Enzymes. Chem Rev 2005;105:2279-328. [DOI: 10.1021/cr030722j] [Cited by in Crossref: 891] [Cited by in F6Publishing: 790] [Article Influence: 55.7] [Reference Citation Analysis]
57 Isin EM, Guengerich FP. Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4. Journal of Biological Chemistry 2006;281:9127-36. [DOI: 10.1074/jbc.m511375200] [Cited by in Crossref: 120] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
58 Taneja G, Chu C, Maturu P, Moorthy B, Ghose R. Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. Drug Metab Dispos 2018;46:397-404. [PMID: 29440179 DOI: 10.1124/dmd.117.079160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
59 Rosecrans R, Dohnal JC. The effect of complimentary and alternative medicine products on laboratory testing. Seminars in Diagnostic Pathology 2009;26:38-48. [DOI: 10.1053/j.semdp.2008.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
60 Yuki H, Honma T, Hata M, Hoshino T. Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4. Bioorg Med Chem 2012;20:775-83. [PMID: 22197672 DOI: 10.1016/j.bmc.2011.12.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
61 Gandhi AS, Guo T, Shah P, Moorthy B, Chow DS, Hu M, Ghose R. CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice. Br J Pharmacol 2012;166:2176-87. [PMID: 22394353 DOI: 10.1111/j.1476-5381.2012.01933.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
62 Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 2008;30:971-82. [DOI: 10.1080/00498250050200122] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
63 Kirwan C, MacPhee I, Philips B. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? Expert Opin Drug Metab Toxicol 2010;6:761-71. [PMID: 20402562 DOI: 10.1517/17425255.2010.482929] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
64 Maher SP, Crouse RB, Conway AJ, Bannister EC, Achyuta AK, Clark AY, Sinatra FL, Cuiffi JD, Adams JH, Kyle DE, Saadi WM. Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes. Biomed Microdevices 2014;16:727-36. [PMID: 24907052 DOI: 10.1007/s10544-014-9877-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
65 Dilger K, Denk A, Heeg MH, Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005;41:595-602. [PMID: 15726657 DOI: 10.1002/hep.20568] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
66 Lee S, Buhler DR. Cloning, tissue distribution, and functional studies of a new cytochrome P450 3A subfamily member, CYP3A45, from rainbow trout (Oncorhynchus mykiss) intestinal ceca. Archives of Biochemistry and Biophysics 2003;412:77-89. [DOI: 10.1016/s0003-9861(03)00029-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
67 Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56-65. [PMID: 16207822 DOI: 10.1124/mol.105.017392] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 6.7] [Reference Citation Analysis]
68 Banerjee M, Chen T. Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1. Biochem Pharmacol 2014;92:389-402. [PMID: 25181459 DOI: 10.1016/j.bcp.2014.08.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
69 Potęga A, Fedejko-Kap B, Mazerska Z. Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305. Xenobiotica 2016;46:1056-65. [PMID: 26928326 DOI: 10.3109/00498254.2016.1147623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
70 Carvalho Henriques B, Yang EH, Lapetina D, Carr MS, Yavorskyy V, Hague J, Aitchison KJ. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? Front Genet 2020;11:491895. [PMID: 33363564 DOI: 10.3389/fgene.2020.491895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
71 Cheng Q, Sohl CD, Yoshimoto FK, Guengerich FP. Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4. J Biol Chem 2012;287:29554-67. [PMID: 22773874 DOI: 10.1074/jbc.M112.390047] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
72 Myllynen P, Immonen E, Kummu M, Vähäkangas K. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opinion on Drug Metabolism & Toxicology 2009;5:1483-99. [DOI: 10.1517/17425250903304049] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
73 Lee AJ, Mills LH, Kosh JW, Conney AH, Zhu BT. NADPH-dependent metabolism of estrone by human liver microsomes. J Pharmacol Exp Ther 2002;300:838-49. [PMID: 11861789 DOI: 10.1124/jpet.300.3.838] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
74 Ramesh M, Bharatam PV. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes. European Journal of Medicinal Chemistry 2014;71:15-23. [DOI: 10.1016/j.ejmech.2013.10.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
75 Oertelt-prigione S, Regitz-zagrosek V. Gender Aspects in Cardiovascular Pharmacology. J of Cardiovasc Trans Res 2009;2:258-66. [DOI: 10.1007/s12265-009-9114-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
76 Habuchi T. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncology 2006;2:233-45. [DOI: 10.2217/14796694.2.2.233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
77 Kumar S, Davydov DR, Halpert JR. Role of cytochrome B5 in modulating peroxide-supported cyp3a4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 2005;33:1131-6. [PMID: 15870379 DOI: 10.1124/dmd.105.004606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
78 Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med 2012;40:1221-8. [PMID: 22067624 DOI: 10.1097/CCM.0b013e31823779f9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
79 Chuo SW, Liou SH, Wang LP, Britt RD, Poulos TL, Sevrioukova IF, Goodin DB. Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution. Biochemistry 2019;58:3903-10. [PMID: 31456404 DOI: 10.1021/acs.biochem.9b00620] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
80 Lv D, Zhao M, Chen L, Yu D, Yun X, Yang Q, Huang X. An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia. Psychiatry Investig 2017;14:360-7. [PMID: 28539955 DOI: 10.4306/pi.2017.14.3.360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Ding X, Lichti K, Staudinger JL. The mycoestrogen zearalenone induces CYP3A through activation of the pregnane X receptor. Toxicol Sci 2006;91:448-55. [PMID: 16547076 DOI: 10.1093/toxsci/kfj163] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
82 Fernando H, Davydov DR, Chin CC, Halpert JR. Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W. Arch Biochem Biophys 2007;460:129-40. [PMID: 17274942 DOI: 10.1016/j.abb.2006.12.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
83 He Y, Zhu L, Ma J, Lin G. Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch Toxicol 2021;95:1917-42. [PMID: 34003343 DOI: 10.1007/s00204-021-03060-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Davydov DR, Botchkareva AE, Davydova NE, Halpert JR. Resolution of two substrate-binding sites in an engineered cytochrome P450eryF bearing a fluorescent probe. Biophys J 2005;89:418-32. [PMID: 15834000 DOI: 10.1529/biophysj.104.058479] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
85 Artelsmair M, Gu C, Lewis RJ, Elmore CS. Synthesis of C-14 labeled GABAA α2/α3 selective partial agonists and the investigation of late-occurring and long-circulating metabolites of GABAA receptor modulator AZD7325. J Labelled Comp Radiopharm 2018;61:415-26. [PMID: 29314165 DOI: 10.1002/jlcr.3602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144:3382-3398. [PMID: 12865317 DOI: 10.1210/en.2003-0192] [Cited by in Crossref: 314] [Cited by in F6Publishing: 291] [Article Influence: 17.4] [Reference Citation Analysis]
87 Xue L, Wang HF, Wang Q, Szklarz GD, Domanski TL, Halpert JR, Correia MA. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. Chem Res Toxicol 2001;14:483-91. [PMID: 11368545 DOI: 10.1021/tx000218z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
88 Chougnet A, Grinkova Y, Ricard D, Sligar S, Woggon WD. Fluorescent probes for rapid screening of potential drug-drug interactions at the CYP3A4 level. ChemMedChem 2007;2:717-24. [PMID: 17357170 DOI: 10.1002/cmdc.200600300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
89 Chen F, Rao XH, Yang JL, Pan MX, Gao Y, Li ZL, Li Y, Zhu YF, Wang Y. Up-regulating CYP3A4 expression in C3A cells by transfection with a novel chimeric regulator of hPXR-p53-AD. PLoS One 2014;9:e95752. [PMID: 24788541 DOI: 10.1371/journal.pone.0095752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
91 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
92 Sevrioukova IF, Poulos TL. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans. 2013;42:3116-3126. [PMID: 23018626 DOI: 10.1039/c2dt31833d] [Cited by in Crossref: 92] [Cited by in F6Publishing: 38] [Article Influence: 10.2] [Reference Citation Analysis]
93 Zanger UM. Cytochrome P450 Polymorphisms. Encyclopedia of Drug Metabolism and Interactions. Hoboken: John Wiley & Sons, Inc.; 2011. [DOI: 10.1002/9780470921920.edm009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
94 Zhang B, Liu Y, Li X. Alteration in the expression of cytochrome P450s (CYP1A1, CYP2E1, and CYP3A11) in the liver of mouse induced by microcystin-LR. Toxins (Basel) 2015;7:1102-15. [PMID: 25831226 DOI: 10.3390/toxins7041102] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
95 Ince I, Knibbe CAJ, Danhof M, de Wildt SN. Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations. Clin Pharmacokinet 2013;52:333-45. [DOI: 10.1007/s40262-013-0041-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
96 Hollingsworth SA, Poulos TL. Molecular dynamics of the P450cam-Pdx complex reveals complex stability and novel interface contacts. Protein Sci 2015;24:49-57. [PMID: 25307478 DOI: 10.1002/pro.2583] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
97 Guengerich FP, Cheng Q. Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol Rev 2011;63:684-99. [PMID: 21737533 DOI: 10.1124/pr.110.003525] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
98 Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3:212-32. [PMID: 28691103 DOI: 10.18053/jctres.03.2017S1.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
99 Gnedenko OV, Ivanov AS, Yablokov EO, Usanov SA, Mukha DV, Sergeev GV, Kuzikov AV, Moskaleva NE, Bulko TV, Shumyantseva VV, Archakov AI. Protein-protein interactions in the systems of cytochromes P450 3A4 and 3A5. Biochem Moscow Suppl Ser B 2014;8:231-6. [DOI: 10.1134/s1990750814030068] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
100 Harrelson JP, Atkins WM, Nelson SD. Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Biochemistry 2008;47:2978-88. [PMID: 18247580 DOI: 10.1021/bi702020y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
101 van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 2009;23:224-31. [PMID: 18794335 DOI: 10.1096/fj.08-114876] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
102 Barretto SA, Lasserre F, Fougerat A, Smith L, Fougeray T, Lukowicz C, Polizzi A, Smati S, Régnier M, Naylies C, Bétoulières C, Lippi Y, Guillou H, Loiseau N, Gamet-Payrastre L, Mselli-Lakhal L, Ellero-Simatos S. Gene Expression Profiling Reveals that PXR Activation Inhibits Hepatic PPARα Activity and Decreases FGF21 Secretion in Male C57Bl6/J Mice. Int J Mol Sci 2019;20:E3767. [PMID: 31374856 DOI: 10.3390/ijms20153767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Blackford SJI, Ng SS, Segal JM, King AJF, Austin AL, Kent D, Moore J, Sheldon M, Ilic D, Dhawan A, Mitry RR, Rashid ST. Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy. Stem Cells Transl Med 2019;8:124-37. [PMID: 30456803 DOI: 10.1002/sctm.18-0084] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
104 Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clinical Therapeutics 2010;32:1372-86. [DOI: 10.1016/j.clinthera.2010.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
105 Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33-60. [PMID: 15634031 DOI: 10.2165/00003088-200544010-00002] [Cited by in Crossref: 199] [Cited by in F6Publishing: 171] [Article Influence: 12.4] [Reference Citation Analysis]
106 Ly JQ, Messick K, Qin A, Takahashi RH, Choo EF. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug–Drug Interactions. Mol Pharmaceutics 2017;14:1754-9. [DOI: 10.1021/acs.molpharmaceut.7b00006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
107 Aasa J, Hu Y, Eklund G, Lindgren A, Baranczewski P, Malmquist J, Turek D, Bueters T. Effect of Solvents on the Time-Dependent Inhibition of CYP3A4 and the Biotransformation of AZD3839 in Human Liver Microsomes and Hepatocytes. Drug Metab Dispos 2012;41:159-69. [DOI: 10.1124/dmd.112.047597] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
108 Álvarez-mercado AI, Sáez-lara MJ, García-mediavilla MV, Sánchez-campos S, Abadía F, Cabello-donayre M, Gil Á, Gonzalez-gallego J, Fontana L. Xenotransplantation of Human Umbilical Cord Blood Mononuclear Cells to Rats with D-Galactosamine-Induced Hepatitis. Cell Transplant 2008;17:845-57. [DOI: 10.3727/096368908786516837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
109 Qu W, Liu X. Identification of cytochrome P450 isoforms involved in the metabolism of artocarpin and assessment of its drug-drug interaction. Biomedical Chromatography 2018;32:e4149. [DOI: 10.1002/bmc.4149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
110 Minegishi G, Kazuki Y, Nitta SI, Miyajima A, Akita H, Kobayashi K. In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice. Xenobiotica 2021;51:764-70. [PMID: 34013847 DOI: 10.1080/00498254.2021.1921314] [Reference Citation Analysis]
111 Van Donge T, Mian P, Tibboel D, Van Den Anker J, Allegaert K. Drug metabolism in early infancy: opioids as an illustration. Expert Opin Drug Metab Toxicol 2018;14:287-301. [PMID: 29363349 DOI: 10.1080/17425255.2018.1432595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
112 Esteban LM, Fong C, Amr D, Cock T, Allison SJ, Flanagan JL, Liddle C, Eisman JA, Gardiner EM. Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform. Biochemical and Biophysical Research Communications 2005;334:9-15. [DOI: 10.1016/j.bbrc.2005.06.054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
113 Kanazawa H, Okada A, Igarashi E, Higaki M, Miyabe T, Sano T, Nishimura R. Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography–mass spectrometry. Journal of Chromatography A 2004;1031:213-8. [DOI: 10.1016/j.chroma.2003.12.039] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
114 Sultana H, Watanabe K, Rana MM, Takashima R, Ohashi A, Komai M, Shirakawa H. Effects of Vitamin K₂ on the Expression of Genes Involved in Bile Acid Synthesis and Glucose Homeostasis in Mice with Humanized PXR. Nutrients 2018;10:E982. [PMID: 30060524 DOI: 10.3390/nu10080982] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
115 McPhail B, Tie Y, Hong H, Pearce BA, Schnackenberg LK, Ge W, Valerio LG, Fuscoe JC, Tong W, Buzatu DA, Wilkes JG, Fowler BA, Demchuk E, Beger RD. Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes. Molecules 2012;17:3383-406. [PMID: 22421792 DOI: 10.3390/molecules17033383] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
116 Lin YS, Lockwood GF, Graham MA, Brian WR, Loi C, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration: . Pharmacogenetics 2001;11:781-91. [DOI: 10.1097/00008571-200112000-00006] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 4.9] [Reference Citation Analysis]
117 Zhang W, Chang Y, Kan Q, Zhang L, Li Z, Lu H, Wang Z, Chu Q, Zhang J. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 2010;66:61-6. [DOI: 10.1007/s00228-009-0726-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
118 Natesh J, Mondal P, Penta D, Abdul Salam AA, Meeran SM. Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation. Comput Biol Med 2021;128:104102. [PMID: 33190011 DOI: 10.1016/j.compbiomed.2020.104102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
119 Fredericks S, Holt DW. Pharmacogenomics of immunosuppressive drug metabolism: . Current Opinion in Nephrology and Hypertension 2003;12:607-13. [DOI: 10.1097/00041552-200311000-00006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
120 Baririan N, Desager J, Petit M, Horsmans Y. CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. Journal of Pharmaceutical and Biomedical Analysis 2006;40:211-4. [DOI: 10.1016/j.jpba.2005.07.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
121 Williams ET, Rodin AS, Strobel HW. Defining relationships between the known members of the cytochrome P450 3A subfamily, including five putative chimpanzee members. Molecular Phylogenetics and Evolution 2004;33:300-8. [DOI: 10.1016/j.ympev.2004.05.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
122 Pondugula SR, Flannery PC, Apte U, Babu JR, Geetha T, Rege SD, Chen T, Abbott KL. Mg 2+ /Mn 2+ -Dependent Phosphatase 1A Is Involved in Regulating Pregnane X Receptor–Mediated Cytochrome p450 3A4 Gene Expression. Drug Metab Dispos 2015;43:385-91. [DOI: 10.1124/dmd.114.062083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
123 Babalola CP, Kolade YT, Olaniyi AA, Adedapo A, Scriba GKE. Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics 2009;34:677-82. [DOI: 10.1111/j.1365-2710.2009.01064.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Shaya L, Jones DE, Wilson JY. CYP3C gene regulation by the aryl hydrocarbon and estrogen receptors in zebrafish. Toxicol Appl Pharmacol 2019;362:77-85. [PMID: 30393146 DOI: 10.1016/j.taap.2018.10.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
125 Cheng Q, DeYonker NJ. QM-Cluster Model Study of the Guaiacol Hydrogen Atom Transfer and Oxygen Rebound with Cytochrome P450 Enzyme GcoA. J Phys Chem B 2021;125:3296-306. [PMID: 33784103 DOI: 10.1021/acs.jpcb.0c10761] [Reference Citation Analysis]
126 Kazuki Y, Kobayashi K, Aueviriyavit S, Oshima T, Kuroiwa Y, Tsukazaki Y, Senda N, Kawakami H, Ohtsuki S, Abe S, Takiguchi M, Hoshiya H, Kajitani N, Takehara S, Kubo K, Terasaki T, Chiba K, Tomizuka K, Oshimura M. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum Mol Genet 2013;22:578-92. [PMID: 23125282 DOI: 10.1093/hmg/dds468] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
127 Alehaideb Z, Chin KC, Yao MC, Law FCP. Predicting the content of anthraquinone bioactive in Rhei rhizome (Rheum officinale Baill.) with the concentration addition model. Saudi Pharm J 2019;27:25-32. [PMID: 30627049 DOI: 10.1016/j.jsps.2018.07.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
128 Hou X, Takahashi K, Kinoshita N, Qiu F, Tanaka K, Komatsu K, Takahashi K, Azuma J. Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1α,25 dihydroxyvitamin D3 treated Caco-2 cells. International Journal of Pharmaceutics 2007;337:169-77. [DOI: 10.1016/j.ijpharm.2006.12.035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
129 Mitsui T, Nemoto T, Miyake T, Nagao S, Ogawa K, Kato M, Ishigai M, Yamada H. A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes. Drug Metab Dispos 2014;42:1540-7. [DOI: 10.1124/dmd.114.057935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
130 Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T, Bartoli F. Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 2003;45:377-87. [DOI: 10.1046/j.1440-169x.2003.00699.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
131 Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS. Variability in Expression of CYP3A5 in Human Fetal Liver. Drug Metab Dispos 2015;43:1286-93. [PMID: 25979262 DOI: 10.1124/dmd.115.064998] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
132 Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62:162-172. [PMID: 12065767 DOI: 10.1124/mol.62.1.162] [Cited by in Crossref: 322] [Cited by in F6Publishing: 297] [Article Influence: 16.9] [Reference Citation Analysis]
133 Karunker I, Benting J, Lueke B, Ponge T, Nauen R, Roditakis E, Vontas J, Gorman K, Denholm I, Morin S. Over-expression of cytochrome P450 CYP6CM1 is associated with high resistance to imidacloprid in the B and Q biotypes of Bemisia tabaci (Hemiptera: Aleyrodidae). Insect Biochemistry and Molecular Biology 2008;38:634-44. [DOI: 10.1016/j.ibmb.2008.03.008] [Cited by in Crossref: 269] [Cited by in F6Publishing: 234] [Article Influence: 20.7] [Reference Citation Analysis]
134 Towles JK, Clark RN, Wahlin MD, Uttamsingh V, Rettie AE, Jackson KD. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. Drug Metab Dispos 2016;44:1584-97. [PMID: 27450182 DOI: 10.1124/dmd.116.070839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
135 Mazzarino M, de la Torre X, Fiacco I, Palermo A, Botrè F. Drug-drug interaction and doping, part 1: An in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene: Drug-drug interaction and doping, part I: toremifene. Drug Test Analysis 2014. [DOI: 10.1002/dta.1592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
136 Zhao J, Das A, Zhang X, Schatz GC, Sligar SG, Van Duyne RP. Resonance Surface Plasmon Spectroscopy:  Low Molecular Weight Substrate Binding to Cytochrome P450. J Am Chem Soc 2006;128:11004-5. [DOI: 10.1021/ja0636082] [Cited by in Crossref: 95] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
137 Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen K, Morley M, Spielman RS. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 2003;33:422-5. [DOI: 10.1038/ng1094] [Cited by in Crossref: 420] [Cited by in F6Publishing: 397] [Article Influence: 23.3] [Reference Citation Analysis]
138 Roberts AG, Yang J, Halpert JR, Nelson SD, Thummel KT, Atkins WM. The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. Biochemistry 2011;50:10804-18. [PMID: 21992114 DOI: 10.1021/bi200924t] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
139 Sica DA, Gehr TW. Rhabdomyolysis and Satin Therapy: Relevance to the Elderly. The American Journal of Geriatric Cardiology 2007;11:48-55. [DOI: 10.1111/j.1076-7460.2002.01422.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
140 Gibson GG, Plant NJ, Swales KE, Ayrton A, El-sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2008;32:165-206. [DOI: 10.1080/00498250110102674] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 11.5] [Reference Citation Analysis]
141 Testa B, Krämer SD. The biochemistry of drug metabolism--an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 2007;4:257-405. [PMID: 17372942 DOI: 10.1002/cbdv.200790032] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 6.5] [Reference Citation Analysis]
142 Minegishi G, Kazuki Y, Yamasaki Y, Okuya F, Akita H, Oshimura M, Kobayashi K. Comparison of the hepatic metabolism of triazolam in wild-type andCyp3a-knockout mice for understanding CYP3A-mediated metabolism inCYP3A-humanised mice in vivo. Xenobiotica 2019;49:1303-10. [DOI: 10.1080/00498254.2018.1560516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 2006;34:1198-207. [PMID: 16638818 DOI: 10.1124/dmd.105.008904] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
144 Wade JH, Jones JD, Lenov IL, Riordan CM, Sligar SG, Bailey RC. Microfluidic platform for efficient Nanodisc assembly, membrane protein incorporation, and purification. Lab Chip 2017;17:2951-9. [PMID: 28767110 DOI: 10.1039/c7lc00601b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Rydberg P, Gloriam DE, Olsen L. The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics 2010;26:2988-9. [PMID: 20947523 DOI: 10.1093/bioinformatics/btq584] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 8.2] [Reference Citation Analysis]
146 Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 2007;35:194-200. [PMID: 17093002 DOI: 10.1124/dmd.106.012831] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 6.8] [Reference Citation Analysis]
147 Li AL, Gao SS, Guo ML, Jing CQ. CYP3A4 and microRNA-122 are involved in the apoptosis of HepG2 cells induced by ILs 1-decyl-3-methylimidazolium bromide. J Biochem Mol Toxicol 2020;34:e22419. [PMID: 31702098 DOI: 10.1002/jbt.22419] [Reference Citation Analysis]
148 Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36. [PMID: 10935688 DOI: 10.1097/00126334-200006010-00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
149 Kijac AZ, Li Y, Sligar SG, Rienstra CM. Magic-angle spinning solid-state NMR spectroscopy of nanodisc-embedded human CYP3A4. Biochemistry 2007;46:13696-703. [PMID: 17985934 DOI: 10.1021/bi701411g] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 6.1] [Reference Citation Analysis]
150 Tong Y, Zeng P, Zhang T, Zhao M, Yu P, Wu B. The transcription factor E4bp4 regulates the expression and activity of Cyp3a11 in mice. Biochemical Pharmacology 2019;163:215-24. [DOI: 10.1016/j.bcp.2019.02.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
151 Han EH, Kim HG, Choi JH, Jang Y, Lee SS, Kwon K, Kim E, Noh K, Jeong TC, Hwang YP, Chung YC, Kang W, Jeong HG. Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein β activation. Mol Nutr Food Res 2012;56:797-809. [DOI: 10.1002/mnfr.201100697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
152 Mayne CG, Arcario MJ, Mahinthichaichan P, Baylon JL, Vermaas JV, Navidpour L, Wen PC, Thangapandian S, Tajkhorshid E. The cellular membrane as a mediator for small molecule interaction with membrane proteins. Biochim Biophys Acta 2016;1858:2290-304. [PMID: 27163493 DOI: 10.1016/j.bbamem.2016.04.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
153 Liu YH, Mo SL, Bi HC, Hu BF, Li CG, Wang YT, Huang L, Huang M, Duan W, Liu JP, Wei MQ, Zhou SF. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica 2011;41:259-80. [PMID: 21117944 DOI: 10.3109/00498254.2010.537395] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
154 Schauss AG, Glavits R, Endres J, Jensen GS, Clewell A. Safety Evaluation of a Proprietary Food-Grade, Dried Fermentate Preparation of Saccharomyces cerevisiae. Int J Toxicol 2012;31:34-45. [DOI: 10.1177/1091581811425195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
155 Ning J, Wang W, Ge G, Chu P, Long F, Yang Y, Peng Y, Feng L, Ma X, James TD. Target Enzyme-Activated Two-Photon Fluorescent Probes: A Case Study of CYP3A4 Using a Two-Dimensional Design Strategy. Angew Chem Int Ed Engl 2019;58:9959-63. [PMID: 31099941 DOI: 10.1002/anie.201903683] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 22.5] [Reference Citation Analysis]
156 Ducharme J, Auclair K. Use of bioconjugation with cytochrome P450 enzymes. Biochim Biophys Acta Proteins Proteom 2018;1866:32-51. [PMID: 28625736 DOI: 10.1016/j.bbapap.2017.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
157 Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7:647-59. [PMID: 30091221 DOI: 10.1002/psp4.12343] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
158 Shah P, Kerns E, Nguyen DT, Obach RS, Wang AQ, Zakharov A, McKew J, Simeonov A, Hop CE, Xu X. An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software. Drug Metab Dispos 2016;44:1653-61. [PMID: 27417180 DOI: 10.1124/dmd.116.072017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
159 Parimoo B, Thomas PE. Epitope Mapping of Rat Cytochrome P450 2B1 Using Glutathione S-Transferase-2B1 Fusion Constructs. Archives of Biochemistry and Biophysics 2000;380:117-25. [DOI: 10.1006/abbi.2000.1922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
160 Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of Nonsteroidal Antiinflammatory Drugs and Risk of Colon Cancer in a Population-based, Case-Control Study of African Americans and Whites. American Journal of Epidemiology 2005;162:548-58. [DOI: 10.1093/aje/kwi248] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
161 Pascussi JM, Dvorák Z, Gerbal-chaloin S, Assenat E, Drocourt L, Maurel P, Vilarem MJ. Regulation of Xenobiotic Detoxification by PXR, CAR, GR, VDR and SHP Receptors: Consequences in Physiology. In: Gossen M, Kaufmann J, Triezenberg SJ, editors. Transcription Factors. Berlin: Springer Berlin Heidelberg; 2004. pp. 409-35. [DOI: 10.1007/978-3-642-18932-6_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
162 Prytuła A, Cransberg K, Raes A. CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health. Pharmacogenomics J 2017;17:481-7. [PMID: 28418012 DOI: 10.1038/tpj.2017.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
163 Zhou C. Novel functions of PXR in cardiometabolic disease. Biochim Biophys Acta 2016;1859:1112-20. [PMID: 26924429 DOI: 10.1016/j.bbagrm.2016.02.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
164 Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol. 2003;59:23-28. [PMID: 12743670 DOI: 10.1007/s00228-003-0575-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
165 Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006;281:17882-9. [PMID: 16608838 DOI: 10.1074/jbc.M601302200] [Cited by in Crossref: 218] [Cited by in F6Publishing: 103] [Article Influence: 14.5] [Reference Citation Analysis]
166 Cuellar S, Vozniak M, Rhodes J, Forcello N, Olszta D. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract 2018;24:433-52. [PMID: 28580869 DOI: 10.1177/1078155217710553] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
167 Zheng X, Wen J, Liu TH, Ou-Yang QG, Cai JP, Zhou HY. Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS. Biochem Res Int 2017;2017:6510232. [PMID: 29387488 DOI: 10.1155/2017/6510232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
168 Calvert H, Twelves C, Ranson M, Plummer R, Fettner S, Pantze M, Ling J, Hamilton M, Lum BL, Rakhit A. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anti-Cancer Drugs 2014;25:832-40. [DOI: 10.1097/cad.0000000000000099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
169 Dong L, Chen Q, Liu X, Wen J, Jiang J, Deng Y. Role of Specificity Protein 1, Hepatocyte Nuclear Factor 1 α , and Pregnane X Receptor in the Basal and Rifampicin-Induced Transcriptional Regulation of Porcine Cytochrome P450 3A46. Drug Metab Dispos 2015;43:1458-67. [DOI: 10.1124/dmd.115.065565] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
170 Chen Y, Tang Y, Nie JZ, Zhang Y, Nie D. Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor. Cancer Chemother Pharmacol 2021;88:985-96. [PMID: 34524495 DOI: 10.1007/s00280-021-04352-9] [Reference Citation Analysis]
171 Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004;201:66-83. [PMID: 15519609 DOI: 10.1016/j.taap.2004.04.017] [Cited by in Crossref: 102] [Cited by in F6Publishing: 85] [Article Influence: 6.0] [Reference Citation Analysis]
172 Kazemnejad S, Allameh A, Soleimani M, Gharehbaghian A, Mohammadi Y, Amirizadeh N, Jazayery M. Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol. 2009;24:278-287. [PMID: 18752558 DOI: 10.1111/j.1440-1746.2008.05530.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 7.2] [Reference Citation Analysis]
173 Konus M, Algso MAS, Kavak E, Kurt‐kızıldoğan A, Yılmaz C, Kivrak A. Design, Synthesis, and In vitro Evaluation of Thieno[a]dibenzothiophene Derivatives. ChemistrySelect 2020;5:3700-9. [DOI: 10.1002/slct.202000685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Åsberg A, Hjelmesæth J, Andersson TB, Sandbu R, Christensen H. Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. Clin Pharmacol Ther 2012;93:275-82. [DOI: 10.1038/clpt.2012.261] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
175 Baas BJ, Denisov IG, Sligar SG. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys 2004;430:218-28. [PMID: 15369821 DOI: 10.1016/j.abb.2004.07.003] [Cited by in Crossref: 131] [Cited by in F6Publishing: 133] [Article Influence: 7.7] [Reference Citation Analysis]
176 Niwa T, Shiraga T, Yamasaki S, Ishibashi K, Ohno Y, Kagayama A. In vitro activation of 7-benzyloxyresorufin O -debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica 2010;33:717-29. [DOI: 10.1080/0049825031000121617] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
177 Groninger E, Meeuwsen-de Boer T, Koopmans P, Uges D, Sluiter W, Veerman A, Kamps W, de Graaf S. Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia. Pediatr Res 2002;52:113-8. [DOI: 10.1203/00006450-200207000-00021] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
178 Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth 2003;90:155-60. [PMID: 12538370 DOI: 10.1093/bja/aeg028] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
179 Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010;6:17-28. [PMID: 19968573 DOI: 10.1517/17425250903379546] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
180 Zangar RC, Kimzey AL, Okita JR, Wunschel DS, Edwards RJ, Kim H, Okita RT. Cytochrome P450 3A Conjugation to Ubiquitin in a Process Distinct from Classical Ubiquitination Pathway. Mol Pharmacol 2002;61:892-904. [DOI: 10.1124/mol.61.4.892] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
181 Roy K, Roy PP. Exploring QSARs for Binding Affinity of Azoles with CYP2B and CYP3A Enzymes Using GFA and G/PLS Techniques: QSAR Studies for Binding Affinity of Azoles. Chemical Biology & Drug Design 2008;71:464-73. [DOI: 10.1111/j.1747-0285.2008.00658.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
182 Wang M, Zhu JY, Chen S, Qing Y, Wu D, Lin YM, Luo JZ, Han W, Li YQ. Effects of co-treatment with sulforaphane and autophagy modulators on uridine 5’-diphospho-glucuronosyltransferase 1A isoforms and cytochrome P450 3A4 expression in Caco-2 human colon cancer cells. Oncol Lett. 2014;8:2407-2416. [PMID: 25364403 DOI: 10.3892/ol.2014.2536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
183 Zhao J, Dasmahapatra AK, Khan SI, Khan IA. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol 2008;120:387-93. [PMID: 18948180 DOI: 10.1016/j.jep.2008.09.016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
184 Panneerselvam S, Yesudhas D, Durai P, Anwar MA, Gosu V, Choi S. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4. Molecules 2015;20:14915-35. [PMID: 26287147 DOI: 10.3390/molecules200814915] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
185 Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J 2009;9:49-60. [PMID: 18825162 DOI: 10.1038/tpj.2008.13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
186 Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E. Effect of Multiple Dosing of Ketoconazole on Pharmacokinetics of Midazolam, a Cytochrome P-450 3A Substrate in Beagle Dogs. Drug Metab Dispos 2002;30:63-8. [DOI: 10.1124/dmd.30.1.63] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
187 Tabassum R. Molecular cloning and 3D model of first cytochrome P450 from CYP3A subfamily in saltwater crocodile (Crocodylus porosus). Biochem Biophys Res Commun 2019;516:1046-52. [PMID: 29054410 DOI: 10.1016/j.bbrc.2017.10.079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Kim J, Min G, Kemper B. Chromatin Assembly Enhances Binding to the CYP2B1Phenobarbital-responsive Unit (PBRU) of Nuclear Factor-1, Which Binds Simultaneously with Constitutive Androstane Receptor (CAR)/Retinoid X Receptor (RXR) and Enhances CAR/RXR-mediated Activation of the PBRU. Journal of Biological Chemistry 2001;276:7559-67. [DOI: 10.1074/jbc.m008090200] [Cited by in Crossref: 36] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
189 Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, Yu L, Zhang A, Wang L, Wang H, Li X, Feng G, He L. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006;7:831-41. [PMID: 16981844 DOI: 10.2217/14622416.7.6.831] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
190 Yang Y, Engkvist O, Llinàs A, Chen H. Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds. J Med Chem 2012;55:3667-77. [DOI: 10.1021/jm201548z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 9.6] [Reference Citation Analysis]
191 Pondugula SR, Dong H, Chen T. Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metab Toxicol 2009;5:861-73. [PMID: 19505191 DOI: 10.1517/17425250903012360] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
192 Bailey DG, Dresser GK. Interactions Between Grapefruit Juice and Cardiovascular Drugs: . American Journal of Cardiovascular Drugs 2004;4:281-97. [DOI: 10.2165/00129784-200404050-00002] [Cited by in Crossref: 131] [Cited by in F6Publishing: 92] [Article Influence: 7.7] [Reference Citation Analysis]
193 Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness. The Journal of Clinical Pharmacology 2003;43:943-67. [DOI: 10.1177/0091270003256065] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 11.8] [Reference Citation Analysis]
194 Jiang J, Wang J, Cai H, Li K, Deng Y. CYP3As catalyze nifedipine oxidation in pig liver microsomes: Enzyme kinetics, inhibition and functional expression. Catalysis Communications 2011;12:694-7. [DOI: 10.1016/j.catcom.2010.12.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
195 Zhuang S, Zhang L, Zhan T, Lu L, Zhao L, Wang H, Morrone JA, Liu W, Zhou R. Binding Specificity Determines the Cytochrome P450 3A4 Mediated Enantioselective Metabolism of Metconazole. J Phys Chem B 2018;122:1176-84. [PMID: 29310431 DOI: 10.1021/acs.jpcb.7b11170] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
196 Kluth D, Landes N, Pfluger P, Müller-Schmehl K, Weiss K, Bumke-Vogt C, Ristow M, Brigelius-Flohé R. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med. 2005;38:507-514. [PMID: 15649653 DOI: 10.1016/j.freeradbiomed.2004.11.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
197 Li A, Yeo K, Welty D, Rong H. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers. Paediatr Drugs 2018;20:181-94. [PMID: 29098603 DOI: 10.1007/s40272-017-0270-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
198 Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006;34:756-64. [PMID: 16455805 DOI: 10.1124/dmd.105.007575] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 5.3] [Reference Citation Analysis]
199 Kriegl JM, Eriksson L, Arnhold T, Beck B, Johansson E, Fox T. Multivariate modeling of cytochrome P450 3A4 inhibition. European Journal of Pharmaceutical Sciences 2005;24:451-63. [DOI: 10.1016/j.ejps.2004.12.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
200 Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chemico-Biological Interactions 2005;151:53-62. [DOI: 10.1016/j.cbi.2003.12.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
201 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 34.3] [Reference Citation Analysis]
202 Faria A, Monteiro R, Azevedo I, Calhau C. Pomegranate Juice Effects on Cytochrome P450s Expression: In Vivo Studies. Journal of Medicinal Food 2007;10:643-9. [DOI: 10.1089/jmf.2007.403] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
203 Mannino GC, Sesti G. Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 2012;16:285-302. [PMID: 23018631 DOI: 10.1007/s40291-012-0002-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
204 Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI. Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. Front Nutr 2021;8:647582. [PMID: 34164422 DOI: 10.3389/fnut.2021.647582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Fernando H, Halpert JR, Davydov DR. Kinetics of electron transfer in the complex of cytochrome P450 3A4 with the flavin domain of cytochrome P450BM-3 as evidence of functional heterogeneity of the heme protein. Arch Biochem Biophys 2008;471:20-31. [PMID: 18086551 DOI: 10.1016/j.abb.2007.11.020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
206 Eid SY, El-Readi MZ, Ashour ML, Wink M. Fallopia japonica, a Natural Modulator, Can Overcome Multidrug Resistance in Cancer Cells. Evid Based Complement Alternat Med 2015;2015:868424. [PMID: 26346937 DOI: 10.1155/2015/868424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
207 Xu X, Lu Q, Yang Y, Martínez MA, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Anadón A, Ares I. A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. Chemosphere 2021;284:131347. [PMID: 34323809 DOI: 10.1016/j.chemosphere.2021.131347] [Reference Citation Analysis]
208 Reuter T, Herold-Mende C, Dyckhoff G, Rigalli JP, Weiss J. Functional role of miR-148a in oropharyngeal cancer: influence on pregnane X receptor and P-glycoprotein expression. J Recept Signal Transduct Res 2019;39:451-9. [PMID: 31771390 DOI: 10.1080/10799893.2019.1694541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
209 Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. Xenobiotica 2008;34:403-13. [DOI: 10.1080/00498250410001685746] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
210 Augustin E, Borowa-Mazgaj B, Kikulska A, Kordalewska M, Pawłowska M. CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells. Acta Pharmacol Sin 2013;34:146-56. [PMID: 23160340 DOI: 10.1038/aps.2012.132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
211 Sevrioukova IF, Poulos TL. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci U S A 2017;114:486-91. [PMID: 28031486 DOI: 10.1073/pnas.1616198114] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
212 Hayes C, Ansbro D, Kontoyianni M. Elucidating Substrate Promiscuity in the Human Cytochrome 3A4. J Chem Inf Model 2014;54:857-69. [DOI: 10.1021/ci4006782] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
213 Lewis DFV, Lake BG, Dickins M, Goldfarb PS. Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions. Xenobiotica 2008;34:549-69. [DOI: 10.1080/00498250410001691325] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
214 Charasson V, Haaz M, Robert J. Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan: Figure 1. Drug Metab Dispos 2002;30:731-3. [DOI: 10.1124/dmd.30.6.731] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
215 Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol. 2013;53:463-474. [PMID: 23436293 DOI: 10.1002/jcph.23] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 10.5] [Reference Citation Analysis]
216 Sevrioukova IF. High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4. Biochemistry 2017;56:3058-67. [PMID: 28590129 DOI: 10.1021/acs.biochem.7b00334] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
217 Nirogi R, Mudigonda K, Kandikere V. Chromatography–mass spectrometry methods for the quantitation of statins in biological samples. Journal of Pharmaceutical and Biomedical Analysis 2007;44:379-87. [DOI: 10.1016/j.jpba.2007.02.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
218 Kumar V, Singh S, Yadav CS, Ahmed RS, Gupta S, Pasha ST, Tripathi AK, Banerjee BD. CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environmental Toxicology and Pharmacology 2010;29:126-30. [DOI: 10.1016/j.etap.2009.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
219 Breslin S, Lowry MC, O'Driscoll L. Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer 2017;116:620-5. [PMID: 28152547 DOI: 10.1038/bjc.2016.445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
220 Zhou C, Poulton EJ, Grün F, Bammler TK, Blumberg B, Thummel KE, Eaton DL. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol. 2007;71:220-229. [PMID: 17028159 DOI: 10.1124/mol.106.029264] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 8.8] [Reference Citation Analysis]
221 Dürr UH, Waskell L, Ramamoorthy A. The cytochromes P450 and b5 and their reductases—Promising targets for structural studies by advanced solid-state NMR spectroscopy. Biochimica et Biophysica Acta (BBA) - Biomembranes 2007;1768:3235-59. [DOI: 10.1016/j.bbamem.2007.08.007] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 7.1] [Reference Citation Analysis]
222 Zhang J, Thi Thanh Ha P, Lou Y, Hoogmartens J, Van Schepdael A. Kinetic study of CYP3A4 activity on verapamil by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 2005;39:612-7. [DOI: 10.1016/j.jpba.2005.04.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
223 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews 2012;64:256-69. [DOI: 10.1016/j.addr.2012.09.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
224 Gómez-lechón MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opinion on Drug Metabolism & Toxicology 2008;4:837-54. [DOI: 10.1517/17425255.4.7.837] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
225 El-Kehdy H, Najar M, De Kock J, Agha DM, Rogiers V, Merimi M, Lagneaux L, Sokal EM, Najimi M. Inflammation Differentially Modulates the Biological Features of Adult Derived Human Liver Stem/Progenitor Cells. Cells 2020;9:E1640. [PMID: 32650454 DOI: 10.3390/cells9071640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
226 Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-sundberg M, Neve EPA. CYP3A4 Catalytic Activity Is Induced in Confluent Huh7 Hepatoma Cells. Drug Metab Dispos 2010;38:995-1002. [DOI: 10.1124/dmd.110.032367] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
227 Coumoul X, Diry M, Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol 2002;64:1513-9. [PMID: 12417264 DOI: 10.1016/s0006-2952(02)01298-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
228 Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279-304. [PMID: 15762770 DOI: 10.2165/00003088-200544030-00005] [Cited by in Crossref: 315] [Cited by in F6Publishing: 279] [Article Influence: 19.7] [Reference Citation Analysis]
229 He H, Nie YL, Li JF, Meng XG, Yang WH, Chen YL, Wang SJ, Ma X, Kan QC, Zhang LR. Developmental regulation of CYP3A4 and CYP3A7 in Chinese Han population. Drug Metab Pharmacokinet 2016;31:433-44. [PMID: 27727071 DOI: 10.1016/j.dmpk.2016.08.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
230 Liu J, Xi H, Jiang Y, Feng Z, Hou L, Li W. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy: Polymorphisms and Ropivacaine Efficacy. Acta Anaesthesiol Scand 2015;59:640-7. [DOI: 10.1111/aas.12501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
231 Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, Arnold FH. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry 2009;15:11723-9. [PMID: 19774562 DOI: 10.1002/chem.200900643] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 9.9] [Reference Citation Analysis]
232 Sevrioukova IF, Poulos TL. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism. Curr Top Med Chem 2014;14:1348-55. [PMID: 24805065 DOI: 10.2174/1568026614666140506120647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
233 Sivertsson L, Edebert I, Palmertz MP, Ingelman-Sundberg M, Neve EP. Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation. Mol Pharmacol 2013;83:659-70. [PMID: 23264496 DOI: 10.1124/mol.112.082305] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
234 Sevrioukova I. Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules. Biochemistry 2019;58:930-9. [PMID: 30676743 DOI: 10.1021/acs.biochem.8b01221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
235 Jover R, Bort R, Gómez‐lechón MJ, Castell JV. Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved. FASEB j 2002;16:1-29. [DOI: 10.1096/fj.02-0195fje] [Cited by in Crossref: 150] [Cited by in F6Publishing: 142] [Article Influence: 7.9] [Reference Citation Analysis]
236 Matter H, Anger LT, Giegerich C, Güssregen S, Hessler G, Baringhaus KH. Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules. Bioorg Med Chem 2012;20:5352-65. [PMID: 22560839 DOI: 10.1016/j.bmc.2012.04.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
237 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
238 de Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomed Chromatogr 2011;25:1091-8. [DOI: 10.1002/bmc.1576] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
239 Brigelius-Flohé R. Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr 2007;2:249-56. [PMID: 18850180 DOI: 10.1007/s12263-007-0055-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
240 Hashimoto M, Kobayashi K, Watanabe M, Kazuki Y, Takehara S, Inaba A, Nitta SI, Senda N, Oshimura M, Chiba K. Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J Lipid Res 2013;54:2060-8. [PMID: 23709690 DOI: 10.1194/jlr.M033464] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
241 Gherezghiher TB, Michalsen B, Chandrasena RE, Qin Z, Sohn J, Thatcher GR, Bolton JL. The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin. Chem Biol Interact 2012;196:1-10. [PMID: 22290292 DOI: 10.1016/j.cbi.2012.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
242 Kurose K, Saeki M, Tohkin M, Hasegawa R. Thyroid hormone receptor mediates human MDR1 gene expression-Identification of the response region essential for gene expression. Arch Biochem Biophys 2008;474:82-90. [PMID: 18395509 DOI: 10.1016/j.abb.2008.03.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
243 Lim YP, Kuo SC, Lai ML, Huang JD. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenet Genomics 2009;19:11-24. [PMID: 19077665 DOI: 10.1097/FPC.0b013e32831665ea] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
244 Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 2005;1687:84-93. [PMID: 15708356 DOI: 10.1016/j.bbalip.2004.11.003] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
245 Kim HH, Ji HY, Lee HW, Kim SA, Lee S, Yi KY, Lee HS. Characterization of cytochrome P450 enzymes and P-glycoprotein involved in the metabolism and transport of a new anti-angiogenic agent KR-31831. Drug Dev Res 2005;66:40-9. [DOI: 10.1002/ddr.20037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Lee HS, Park EJ, Ji HY, Kim SY, Im G, Lee SM, Jang IJ. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 2008;38:21-33. [DOI: 10.1080/00498250701708521] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
247 Westlind-johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-sundberg M. COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM. Drug Metab Dispos 2003;31:755-61. [DOI: 10.1124/dmd.31.6.755] [Cited by in Crossref: 171] [Cited by in F6Publishing: 159] [Article Influence: 9.5] [Reference Citation Analysis]
248 Kumar S, Liu H, Halpert JR. Engineering of Cytochrome P450 3A4 for Enhanced Peroxide-Mediated Substrate Oxidation Using Directed Evolution and Site-Directed Mutagenesis. Drug Metab Dispos 2006;34:1958-65. [DOI: 10.1124/dmd.106.012054] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
249 Chatopadhyay P, Pandey A, Chaurasia AK, Upadhyay A, Karmakar S, Singh L. Hepatic hyperplasia and damages induces by zearalenone Fusarium mycotoxins in BALB/c mice. Arq Gastroenterol 2012;49:77-81. [DOI: 10.1590/s0004-28032012000100013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
250 Gao Y, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, Mosley RT. Attenuating pregnane X receptor (PXR) activation: A molecular modelling approach. Xenobiotica 2008;37:124-38. [DOI: 10.1080/00498250601050412] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
251 Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L, Liu X. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci 2013;102:2819-36. [PMID: 23760985 DOI: 10.1002/jps.23613] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
252 Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenetics and Genomics 2009;19:877-83. [DOI: 10.1097/fpc.0b013e32833225e7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
253 Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 2000;153:1-10. [DOI: 10.1016/s0300-483x(00)00300-0] [Cited by in Crossref: 141] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
254 Kim B, Moon J, Choi MH, Yang HH, Lee S, Lim KS, Yoon SH, Yu K, Jang I, Cho J. Global Metabolomics and Targeted Steroid Profiling Reveal That Rifampin, a Strong Human PXR Activator, Alters Endogenous Urinary Steroid Markers. J Proteome Res 2013;12:1359-68. [DOI: 10.1021/pr301021p] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
255 Stefanski A, Mevissen M, Möller A, Kuehni-boghenbor K, Schmitz A. Induction of cytochrome P450 enzymes in primary equine hepatocyte culture. Toxicology in Vitro 2013;27:2023-30. [DOI: 10.1016/j.tiv.2013.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
256 Kaminsky LS, Zhang Q. THE SMALL INTESTINE AS A XENOBIOTIC-METABOLIZING ORGAN. Drug Metab Dispos 2003;31:1520-5. [DOI: 10.1124/dmd.31.12.1520] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 9.3] [Reference Citation Analysis]
257 Wu Q, Ning B, Xuan J, Ren Z, Guo L, Bryant MS. The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. Toxicol Lett 2016;253:55-62. [PMID: 27113703 DOI: 10.1016/j.toxlet.2016.04.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
258 Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. [PMID: 10668858 DOI: 10.2165/00003088-200038010-00003] [Cited by in Crossref: 603] [Cited by in F6Publishing: 504] [Article Influence: 28.7] [Reference Citation Analysis]
259 Hu P, Zhang M, Napoli JL. Ontogeny of rdh9 (Crad3) expression: ablation causes changes in retinoid and steroid metabolizing enzymes, but RXR and androgen signaling seem normal. Biochim Biophys Acta 2007;1770:694-705. [PMID: 17270348 DOI: 10.1016/j.bbagen.2006.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
260 Polic V, Auclair K. Controlling substrate specificity and product regio- and stereo-selectivities of P450 enzymes without mutagenesis. Bioorg Med Chem 2014;22:5547-54. [PMID: 25035263 DOI: 10.1016/j.bmc.2014.06.034] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
261 Giri SK, Yadav A, Kumar A, Dev K, Gulati S, Gupta R, Aggarwal N, Gautam SK. Polymorphic variation of CYP1A1 and CYP1B1 genes in a Haryana population. Biochem Genet 2013;51:853-64. [PMID: 23839087 DOI: 10.1007/s10528-013-9612-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Kang D, Zhao T, Wang Z, Feng D, Zhang H, Huang B, Wu G, Wei F, Zhou Z, Jing L, Zuo X, Tian Y, Poongavanam V, Kongsted J, De Clercq E, Pannecouque C, Zhan P, Liu X. Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Commun Chem 2019;2. [DOI: 10.1038/s42004-019-0174-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
263 Podszun MC, Grebenstein N, Hofmann U, Frank J. High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs. Toxicology and Applied Pharmacology 2013;266:452-8. [DOI: 10.1016/j.taap.2012.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
264 van Waterschoot RA, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev. 2011;63:390-410. [PMID: 21490128 DOI: 10.1124/pr.110.002584] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
265 Krüger RA, Terpstra AS, Sutherland TC. Synthesis and spectroelectrochemical investigation of two tetraarylporphyrins. Can J Chem 2011;89:214-20. [DOI: 10.1139/v10-098] [Cited by in Crossref: 8] [Article Influence: 0.8] [Reference Citation Analysis]
266 Zhou D, Sunzel M, Ribadeneira MD, Smith MA, Desai D, Lin J, Grimm SW. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. Br J Clin Pharmacol 2012;74:98-108. [PMID: 22122233 DOI: 10.1111/j.1365-2125.2011.04155.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
267 Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004;44:1083-105. [PMID: 15342610 DOI: 10.1177/0091270004268128] [Cited by in Crossref: 136] [Cited by in F6Publishing: 122] [Article Influence: 8.5] [Reference Citation Analysis]
268 Lin QM, Li YH, Lu XR, Wang R, Pang NH, Xu RA, Cai JP, Hu GX. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. Chem Res Toxicol 2019;32:1583-90. [PMID: 31293154 DOI: 10.1021/acs.chemrestox.9b00100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
269 Zhi D, Feng P, Sun J, Guo F, Zhang R, Zhao X, Li B. The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides. European Journal of Pharmaceutical Sciences 2015;76:149-55. [DOI: 10.1016/j.ejps.2015.05.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
270 Angeles PC, Robertsen I, Seeberg LT, Krogstad V, Skattebu J, Sandbu R, Åsberg A, Hjelmesaeth J. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. Obes Rev 2019;20:1299-311. [PMID: 31232513 DOI: 10.1111/obr.12869] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
271 Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 2004;34:391-402. [PMID: 15370956 DOI: 10.1080/00498250410001685755] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
272 van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CM, Schellens JH, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 2005;33:892-5. [PMID: 15845749 DOI: 10.1124/dmd.105.004721] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
273 Kieler-ferguson HM, Fréchet JMJ, Szoka Jr FC. Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs: Clinical developments of chemotherapeutic nanomedicines. WIREs Nanomed Nanobiotechnol 2013;5:130-8. [DOI: 10.1002/wnan.1209] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
274 Velenosi TJ, Fu AY, Luo S, Wang H, Urquhart BL. Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease. Drug Metab Dispos 2012;40:1508-14. [PMID: 22573661 DOI: 10.1124/dmd.112.045245] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
275 Ma X, Qu X, Zhu W, Li YS, Yuan S, Zhang H, Liu J, Wang P, Lai CS, Zanella F, Feng GS, Sheikh F, Chien S, Chen S. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci U S A 2016;113:2206-11. [PMID: 26858399 DOI: 10.1073/pnas.1524510113] [Cited by in Crossref: 399] [Cited by in F6Publishing: 353] [Article Influence: 79.8] [Reference Citation Analysis]
276 Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001;40:833-68. [PMID: 11735605 DOI: 10.2165/00003088-200140110-00004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 71] [Article Influence: 5.2] [Reference Citation Analysis]
277 Donato MT, Klocke R, Castell JV, Stenzel K, Paul D, Gómez-lechón MJ. Constitutive and inducible expression of CYP enzymes in immortal hepatocytes derived from SV40 transgenic mice. Xenobiotica 2008;33:459-73. [DOI: 10.1080/0049825031000076168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
278 Wang K, Chen S, Xie W, Wan YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 2008;75:2204-13. [PMID: 18400206 DOI: 10.1016/j.bcp.2008.02.030] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
279 Atkins WM. Mechanisms of promiscuity among drug metabolizing enzymes and drug transporters. FEBS J 2020;287:1306-22. [PMID: 31663687 DOI: 10.1111/febs.15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
280 Stevens LJ, van Lipzig MMH, Erpelinck SLA, Pronk A, van Gorp J, Wortelboer HM, van de Steeg E. A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes. Eur J Pharm Sci 2019;137:104989. [PMID: 31301485 DOI: 10.1016/j.ejps.2019.104989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
281 Hadrup N, Pedersen M, Skov K, Hansen NL, Berthelsen LO, Kongsbak K, Boberg J, Dybdahl M, Hass U, Frandsen H, Vinggaard AM. Perfluorononanoic acid in combination with 14 chemicals exerts low-dose mixture effects in rats. Arch Toxicol 2016;90:661-75. [DOI: 10.1007/s00204-015-1452-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
282 Rekka E, Evdokimova E, Eeckhaudt S, Calderon PB. Reoxygenation after cold hypoxic storage of cultured precision-cut rat liver slices: effects on cellular metabolism and drug biotransformation. Biochim Biophys Acta 2001;1568:245-51. [PMID: 11786231 DOI: 10.1016/s0304-4165(01)00225-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
283 Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet 2013;52:399-414. [PMID: 23420518 DOI: 10.1007/s40262-013-0040-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
284 Sharma T, Banerjee BD, Thakur GK, Guleria K, Mazumdar D. Polymorphism of xenobiotic metabolizing gene and susceptibility of epithelial ovarian cancer with reference to organochlorine pesticides exposure. Exp Biol Med (Maywood) 2019;244:1446-53. [PMID: 31569996 DOI: 10.1177/1535370219878652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012;83:1112-1126. [PMID: 22326308 DOI: 10.1016/j.bcp.2012.01.030] [Cited by in Crossref: 135] [Cited by in F6Publishing: 132] [Article Influence: 15.0] [Reference Citation Analysis]
286 Monroe KR, Murphy SP, Henderson BE, Kolonel LN, Stanczyk FZ, Adlercreutz H, Pike MC. Dietary Fiber Intake and Endogenous Serum Hormone Levels in Naturally Postmenopausal Mexican American Women: The Multiethnic Cohort Study. Nutrition and Cancer 2007;58:127-35. [DOI: 10.1080/01635580701327935] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
287 Carpio Arévalo JM, Amorim JC. An in-silico analysis reveals 7,7'-bializarin as a promising DNA gyrase B inhibitor on Gram-positive and Gram-negative bacteria. Comput Biol Med 2021;135:104626. [PMID: 34246160 DOI: 10.1016/j.compbiomed.2021.104626] [Reference Citation Analysis]
288 Šimić I, Potočnjak I, Kraljičković I, Stanić Benić M, Čegec I, Juričić Nahal D, Ganoci L, Božina N. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. Pharmacogenomics 2016;17:1385-9. [PMID: 27469576 DOI: 10.2217/pgs-2016-0069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
289 Sevrioukova IF. Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin. Int J Mol Sci 2019;20:E4245. [PMID: 31480231 DOI: 10.3390/ijms20174245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
290 Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-4. [PMID: 17261409 DOI: 10.1016/j.amjcard.2006.08.051] [Cited by in Crossref: 142] [Cited by in F6Publishing: 130] [Article Influence: 9.5] [Reference Citation Analysis]
291 Li L, Sinz MW, Zimmermann K, Wang H. An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J Pharmacol Exp Ther 2012;340:688-97. [PMID: 22171088 DOI: 10.1124/jpet.111.188854] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
292 Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 2005;822:27-32. [PMID: 15993663 DOI: 10.1016/j.jchromb.2005.05.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
293 Riffel AK, Schuenemann E, Vyhlidal CA. Regulation of the CYP3A4 and CYP3A7 promoters by members of the nuclear factor I transcription factor family. Mol Pharmacol 2009;76:1104-14. [PMID: 19706729 DOI: 10.1124/mol.109.055699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
294 Verslycke T, Goldstone JV, Stegeman JJ. Isolation and phylogeny of novel cytochrome P450 genes from tunicates (Ciona spp.): A CYP3 line in early deuterostomes? Molecular Phylogenetics and Evolution 2006;40:760-71. [DOI: 10.1016/j.ympev.2006.04.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
295 Won EJ, Rhee JS, Shin KH, Jung JH, Shim WJ, Lee YM, Lee JS. Expression of three novel cytochrome P450 (CYP) and antioxidative genes from the polychaete, Perinereis nuntia exposed to water accommodated fraction (WAF) of Iranian crude oil and benzo[a]pyrene. Mar Environ Res 2013;90:75-84. [PMID: 23871518 DOI: 10.1016/j.marenvres.2013.05.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
296 Rochat B. Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance: Focus on Tamoxifen, Paclitaxel and Imatinib Metabolism. Clinical Pharmacokinetics 2005;44:349-66. [DOI: 10.2165/00003088-200544040-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
297 Lee SJ, van der Heiden IP, Goldstein JA, van Schaik RH. A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos 2007;35:67-71. [PMID: 17035598 DOI: 10.1124/dmd.106.012310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
298 Zhao J, Das A, Schatz GC, Sligar SG, Van Duyne RP. Resonance Localized Surface Plasmon Spectroscopy: Sensing Substrate and Inhibitor Binding to Cytochrome P450. J Phys Chem C 2008;112:13084-8. [DOI: 10.1021/jp801719c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
299 Zhou D, Andersson TB, Grimm SW. In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics. Drug Metab Dispos 2011;39:703-10. [DOI: 10.1124/dmd.110.037143] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
300 Plucinski L, Ranjan Gartia M, Arnold WR, Ameen A, Chang T, Hsiao A, Logan Liu G, Das A. Substrate binding to cytochrome P450-2J2 in Nanodiscs detected by nanoplasmonic Lycurgus cup arrays. Biosensors and Bioelectronics 2016;75:337-46. [DOI: 10.1016/j.bios.2015.07.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
301 Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps. Journal of Biological Chemistry 2005;280:19496-506. [DOI: 10.1074/jbc.m501854200] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
302 Jan YH, Mishin V, Busch CM, Thomas PE. Generation of specific antibodies and their use to characterize sex differences in four rat P450 3A enzymes following vehicle and pregnenolone 16alpha-carbonitrile treatment. Arch Biochem Biophys. 2006;446:101-110. [PMID: 16448623 DOI: 10.1016/j.abb.2005.11.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
303 Rendic SP, Guengerich FP. Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Arch Toxicol 2021;95:395-472. [PMID: 33459808 DOI: 10.1007/s00204-020-02971-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
304 Shang W, Liu J, Chen R, Ning R, Xiong J, Liu W, Mao Z, Hu G, Yang J. Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells. Xenobiotica 2015;46:393-405. [DOI: 10.3109/00498254.2015.1082209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
305 Teschke R, Zhang L, Melzer L, Schulze J, Eickhoff A. Green tea extract and the risk of drug-induced liver injury. Expert Opinion on Drug Metabolism & Toxicology 2014;10:1663-76. [DOI: 10.1517/17425255.2014.971011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
306 Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, Namiki N, Odagiri K, Watanabe H. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci 2019;139:361-6. [PMID: 30902567 DOI: 10.1016/j.jphs.2019.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
307 Yang T, Li C, Zhang L, Li M, Zhou P. A promising hepatocyte-like cell line, CCL-13, exhibits good liver function both in vitro and in an acute liver failure model. Transplant Proc 2013;45:688-94. [PMID: 23498808 DOI: 10.1016/j.transproceed.2012.11.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
308 Shi J, Montay G, Leroy B, Bhargava VO. Effects of Itraconazole or Grapefruit Juice on the Pharmacokinetics of Telithromycin. Pharmacotherapy 2005;25:42-51. [DOI: 10.1592/phco.25.1.42.55621] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
309 Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002;30:757-762. [PMID: 12065433 DOI: 10.1124/dmd.30.7.757] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
310 McArthur AG, Hegelund T, Cox RL, Stegeman JJ, Liljenberg M, Olsson U, Sundberg P, Celander MC. Phylogenetic analysis of the cytochrome P450 3 (CYP3) gene family. J Mol Evol 2003;57:200-11. [PMID: 14562963 DOI: 10.1007/s00239-003-2466-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
311 Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 2003;3:291-301. [PMID: 14575518 DOI: 10.2165/00129785-200303050-00001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
312 Ferdinand KC. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Expert Opin Pharmacother 2005;6:1897-910. [PMID: 16144509 DOI: 10.1517/14656566.6.11.1897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
313 Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, Adams PC, Kim RB, Tirona RG. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. Mol Pharmacol 2016;90:437-46. [PMID: 27482056 DOI: 10.1124/mol.116.104687] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
314 Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos 2015;43:1484-90. [DOI: 10.1124/dmd.115.065979] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
315 Andreas CJ, Tomaszewska I, Muenster U, van der Mey D, Mueck W, Dressman JB. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine. Eur J Pharm Biopharm 2016;105:193-202. [PMID: 27322002 DOI: 10.1016/j.ejpb.2016.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
316 Guo J, Gu C, Zhou D, Elmore CS, Bui KH, Grimm SW. In Vitro and In Vivo Metabolism of a Selective δ-Opioid Receptor. Drug Metab Dispos 2011;39:1883-94. [DOI: 10.1124/dmd.111.040980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
317 Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003;43:414-22. [PMID: 12723462 DOI: 10.1177/0091270003251864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
318 Kellie JF, Karlinsey MZ. Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS. Bioanalysis 2018;10:1877-90. [DOI: 10.4155/bio-2018-0113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
319 Basheer L, Kerem Z. Interactions between CYP3A4 and Dietary Polyphenols. Oxid Med Cell Longev 2015;2015:854015. [PMID: 26180597 DOI: 10.1155/2015/854015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 12.8] [Reference Citation Analysis]
320 Hendricks NR, Waryo TT, Arotiba O, Jahed N, Baker PG, Iwuoha EI. Microsomal cytochrome P450-3A4 (CYP3A4) nanobiosensor for the determination of 2,4-dichlorophenol—An endocrine disruptor compound. Electrochimica Acta 2009;54:1925-31. [DOI: 10.1016/j.electacta.2008.09.073] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
321 Davydov DR. Microsomal monooxygenase in apoptosis: another target for cytochrome c signaling? Trends Biochem Sci 2001;26:155-60. [PMID: 11246020 DOI: 10.1016/s0968-0004(00)01749-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
322 Yuan R, Zhang X, Deng Q, Wu Y, Xiang G. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta 2011;412:755-60. [PMID: 21223952 DOI: 10.1016/j.cca.2010.12.038] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
323 Gervasini G, Vizcaino S, Carrillo JA, Caballero MJ, Benitez J. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 2006;62:177-86. [PMID: 16842392 DOI: 10.1111/j.1365-2125.2006.02578.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
324 Elizondo G, Medina-Díaz IM. Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci 2003;73:141-9. [PMID: 12738030 DOI: 10.1016/s0024-3205(03)00262-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
325 Schmitz G, Drobnik W. Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy. Clinical Chemistry and Laboratory Medicine 2003;41. [DOI: 10.1515/cclm.2003.088] [Cited by in Crossref: 43] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
326 Cheng X, Ivanov I. Molecular dynamics. Methods Mol Biol 2012;929:243-85. [PMID: 23007433 DOI: 10.1007/978-1-62703-050-2_11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
327 Nisha AR, Hazilawati H, Mohd Azmi ML, Noordin MM. The induction of aryl hydrocarbon receptor (AHR) in immune organs of developing chicks by polycyclic aromatic hydrocarbons. Toxicol Mech Methods 2018;28:461-6. [PMID: 29606035 DOI: 10.1080/15376516.2018.1459992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
328 Langman L, van Gelder T, van Schaik RH. Pharmacogenomics aspect of immunosuppressant therapy. Personalized Immunosuppression in Transplantation. Elsevier; 2016. pp. 109-24. [DOI: 10.1016/b978-0-12-800885-0.00005-9] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
329 Misaka S, Uchida S, Imai H, Inui N, Nishio S, Ohashi K, Watanabe H, Yamada S. Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. Clinical and Experimental Pharmacology and Physiology 2010;37:290-5. [DOI: 10.1111/j.1440-1681.2009.05285.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
330 Guengerich FP, McCarty KD, Chapman JG. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process. J Biol Chem 2021;296:100223. [PMID: 33449875 DOI: 10.1074/jbc.RA120.016855] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Mandlekar SV, Rose AV, Cornelius G, Sleczka B, Caporuscio C, Wang J, Marathe PH. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica 2008;37:923-42. [DOI: 10.1080/00498250701570269] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
332 Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH. Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir. J Pharmacol Exp Ther 2003;304:596-602. [DOI: 10.1124/jpet.102.044388] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
333 Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 2008;36:2506-12. [PMID: 18799805 DOI: 10.1124/dmd.108.022723] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
334 Houck KA, Kavlock RJ. Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol Appl Pharmacol 2008;227:163-78. [PMID: 18063003 DOI: 10.1016/j.taap.2007.10.022] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
335 Pelkonen O. Human CYPs: in vivo and clinical aspects. Drug Metabolism Reviews 2002;34:37-46. [DOI: 10.1081/dmr-120001388] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
336 Maia M, Resende DISP, Durães F, Pinto MMM, Sousa E. Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities. Eur J Med Chem 2021;210:113085. [PMID: 33310284 DOI: 10.1016/j.ejmech.2020.113085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
337 Sica DA, Gehr TW. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient: . Current Opinion in Nephrology and Hypertension 2002;11:123-33. [DOI: 10.1097/00041552-200203000-00001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
338 Ho HK, Chan JC, Hardy KD, Chan EC. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev 2015;47:21-8. [PMID: 25639891 DOI: 10.3109/03602532.2014.1003648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
339 Sun M, Zhang Q, Yang X, Qian SY, Guo B. Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism. Mol Cancer Ther 2016;15:2086-95. [PMID: 27458137 DOI: 10.1158/1535-7163.MCT-16-0095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
340 Piccinato CA, Neme RM, Torres N, Silvério R, Pazzini VB, Rosa E Silva JC, Ferriani RA. Is cytochrome P450 3A4 regulated by menstrual cycle hormones in control endometrium and endometriosis? Mol Cell Biochem 2017;427:81-9. [PMID: 27995413 DOI: 10.1007/s11010-016-2899-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
341 Viiri LE, Rantapero T, Kiamehr M, Alexanova A, Oittinen M, Viiri K, Niskanen H, Nykter M, Kaikkonen MU, Aalto-Setälä K. Extensive reprogramming of the nascent transcriptome during iPSC to hepatocyte differentiation. Sci Rep 2019;9:3562. [PMID: 30837492 DOI: 10.1038/s41598-019-39215-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
342 Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005;19:371-80. [DOI: 10.1097/01.aids.0000161766.13782.2f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
343 Rekka E, Evdokimova E, Eeckhoudt S, Labar G, Calderon PB. Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices. Biochem Pharmacol 2002;64:633-43. [PMID: 12167482 DOI: 10.1016/s0006-2952(02)01258-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Yang Y, Li P, Zhang Z, Wang Z, Liu L, Liu X. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. Int J Mol Sci 2020;21:E7023. [PMID: 32987693 DOI: 10.3390/ijms21197023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
345 Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33 Suppl 2:10-6. [PMID: 14641551 DOI: 10.1046/j.1365-2362.33.s2.2.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
346 Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 2008;62:529-37. [PMID: 17992531 DOI: 10.1007/s00280-007-0634-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
347 Srinivas NR. Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications. Biomed Chromatogr 2006;20:466-91. [DOI: 10.1002/bmc.680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
348 Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Adv 2019;3:908-16. [PMID: 30898762 DOI: 10.1182/bloodadvances.2018022921] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
349 Peng HM, Auchus RJ. Two surfaces of cytochrome b5 with major and minor contributions to CYP3A4-catalyzed steroid and nifedipine oxygenation chemistries. Arch Biochem Biophys 2014;541:53-60. [PMID: 24256945 DOI: 10.1016/j.abb.2013.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
350 Morisaki T, Hou X, Takahashi K, Takahashi K. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids. Journal of Pharmacy and Pharmacology 2013;65:1526-35. [DOI: 10.1111/jphp.12127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
351 Morales-olivas FJ, Estañ L. Interacciones medicamentosas. Nuevos aspectos. Medicina Clínica 2006;127:269-75. [DOI: 10.1157/13091269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
352 Hou XL, Hayashi-Nakamura E, Takatani-Nakase T, Tanaka K, Takahashi K, Komatsu K, Takahashi K. Curdione Plays an Important Role in the Inhibitory Effect of Curcuma aromatica on CYP3A4 in Caco-2 Cells. Evid Based Complement Alternat Med 2011;2011:913898. [PMID: 21785639 DOI: 10.1093/ecam/nep229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
353 Polic V, Sevrioukova IF, Auclair K. Steroid bioconjugation to a CYP3A4 allosteric site and its effect on substrate binding and coupling efficiency. Arch Biochem Biophys 2018;653:90-6. [PMID: 29958895 DOI: 10.1016/j.abb.2018.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
354 Schmidt B, Faymonville T, Gembé E, Joußen N, Schuphan I. Comparison of the Biotransformation of the14C-Labelled Insecticide Carbaryl by Non-Transformed and Human CYP1A1-, CYP1A2-, and CYP3A4-Transgenic Cell Cultures ofNicotiana tabacum. C&B 2006;3:878-96. [DOI: 10.1002/cbdv.200690091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
355 Ragueneau-majlessi I, Levy R, Janik F. Levetiracetam Does Not Alter the Pharmacokinetics of an Oral Contraceptive in Healthy Women. Epilepsia 2002;43:697-702. [DOI: 10.1046/j.1528-1157.2002.57701.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
356 Christiansen A, Backensfeld T, Denner K, Weitschies W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. European Journal of Pharmaceutics and Biopharmaceutics 2011;78:166-72. [DOI: 10.1016/j.ejpb.2010.12.033] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
357 Wang L, Li F, Lu J, Li G, Li D, Zhong XB, Guo GL, Ma X. The Chinese herbal medicine Sophora flavescens activates pregnane X receptor. Drug Metab Dispos 2010;38:2226-31. [PMID: 20736322 DOI: 10.1124/dmd.110.035253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
358 Jeon S, Kim KH, Yun CH, Hong BW, Chang YS, Han HS, Yoon YS, Choi WB, Kim S, Lee AY. An NH2-terminal truncated cytochrome P450 CYP3A4 showing catalytic activity is present in the cytoplasm of human liver cells. Exp Mol Med 2008;40:254-60. [PMID: 18446064 DOI: 10.3858/emm.2008.40.2.254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
359 Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2005;1082:6-14. [PMID: 16038189 DOI: 10.1016/j.chroma.2005.01.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
360 Kumar S, Halpert JR. Use of directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts. Biochemical and Biophysical Research Communications 2005;338:456-64. [DOI: 10.1016/j.bbrc.2005.08.080] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
361 Hayakawa S, Matsumura H, Nakamura N, Yohda M, Ohno H. Identification of the rate-limiting step of the peroxygenase reactions catalyzed by the thermophilic cytochrome P450 from Sulfolobus tokodaii strain 7. FEBS J 2014;281:1409-16. [DOI: 10.1111/febs.12712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
362 Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573-82. [PMID: 12975492 DOI: 10.1124/jpet.103.054841] [Cited by in Crossref: 284] [Cited by in F6Publishing: 241] [Article Influence: 15.8] [Reference Citation Analysis]
363 Castell JV, Jover R, Martínez-Jiménez CP, Gómez-Lechón MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006;2:183-212. [PMID: 16866607 DOI: 10.1517/17425255.2.2.183] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 10.3] [Reference Citation Analysis]
364 Cui Y, Tian X, Ning J, Wang C, Yu Z, Wang Y, Huo X, Jin L, Deng S, Zhang B, Ma X. Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation. AAPS J 2016;18:1273-88. [DOI: 10.1208/s12248-016-9945-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
365 Greenblatt DJ, von Moltke LL. Clinical Studies of Drug–Drug Interactions: Design and Interpretation. In: Pang KS, Rodrigues AD, Peter RM, editors. Enzyme- and Transporter-Based Drug-Drug Interactions. New York: Springer; 2010. pp. 625-49. [DOI: 10.1007/978-1-4419-0840-7_24] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
366 van Rijssen TJ, van Dijk EH, Yzer S, Ohno-matsui K, Keunen JE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJ. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research 2019;73:100770. [DOI: 10.1016/j.preteyeres.2019.07.003] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 43.0] [Reference Citation Analysis]
367 Ferraresso M, Turolo S, Ghio L, Tirelli AS, Belingheri M, Villa R, Groppali E, Edefonti A. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors. Clin Exp Hypertens. 2011;33:359-365. [PMID: 21851254 DOI: 10.3109/10641963.2011.561896] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
368 Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 2013;69:507-13. [PMID: 22968811 DOI: 10.1007/s00228-012-1388-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
369 Wacher VJ, Silverman JA, Wong S, Tran-tau P, Chan AO, Chai A, Yu X, O'mahony D, Ramtoola Z. Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by d-α-Tocopheryl Poly(Ethylene Glycol 1000) Succinate. J Pharmacol Exp Ther 2002;303:308-13. [DOI: 10.1124/jpet.102.036541] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
370 Nibourg GAA, Huisman MT, van der Hoeven TV, van Gulik TM, Chamuleau RAFM, Hoekstra R. Stable overexpression of Pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application: PXR Overexpression in HEPG2 for a Bioartificial Liver. Liver Transpl 2010;16:1075-85. [DOI: 10.1002/lt.22110] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
371 Justenhoven C, Winter S, Hamann U, Haas S, Fischer HP, Pesch B, Brüning T, Ko YD, Brauch H; GENICA Network. The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors. Cancer 2010;116:5358-64. [PMID: 20715157 DOI: 10.1002/cncr.25508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
372 Augustin E, Pawłowska M, Polewska J, Potega A, Mazerska Z. Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells. Cell Biol Int 2013;37:109-20. [PMID: 23319370 DOI: 10.1002/cbin.10018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
373 Zhang J, Ha PTT, Lou Y, Hoogmartens J, Van Schepdael A. Kinetic study of cytochrome P450 3A4 activity on warfarin by capillary electrophoresis with fluorescence detection. Journal of Chromatography A 2005;1082:235-9. [DOI: 10.1016/j.chroma.2005.05.071] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
374 Gonzalez FJ, Fang ZZ, Ma X. Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opin Drug Metab Toxicol 2015;11:869-81. [PMID: 25836352 DOI: 10.1517/17425255.2015.1032245] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
375 Kim YM, Park TS, Kim SG. The role of sphingolipids in drug metabolism and transport. Expert Opin Drug Metab Toxicol 2013;9:319-31. [PMID: 23289866 DOI: 10.1517/17425255.2013.748749] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
376 Greenblatt DJ, von Moltke LL. Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs. The Journal of Clinical Pharmacology 2008;48:1350-5. [DOI: 10.1177/0091270008323754] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
377 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews 2002;54:1271-94. [DOI: 10.1016/s0169-409x(02)00066-2] [Cited by in Crossref: 672] [Cited by in F6Publishing: 215] [Article Influence: 35.4] [Reference Citation Analysis]
378 Dilger K, Halter J, Bertz H, Lopez-Lazaro L, Gratwohl A, Finke J. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009;15:336-43. [PMID: 19203724 DOI: 10.1016/j.bbmt.2008.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
379 Sevrioukova IF, Poulos TL. Anion-Dependent Stimulation of CYP3A4 Monooxygenase. Biochemistry 2015;54:4083-96. [PMID: 26066995 DOI: 10.1021/acs.biochem.5b00510] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
380 Tsalkova TN, Davydova NY, Halpert JR, Davydov DR. Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe. Biochemistry 2007;46:106-19. [PMID: 17198380 DOI: 10.1021/bi061944p] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
381 Zangar RC, Kocarek TA, Shen S, Bollinger N, Dahn MS, Lee DW. Suppression of cytochrome P450 3A protein levels by proteasome inhibitors. J Pharmacol Exp Ther 2003;305:872-9. [PMID: 12626652 DOI: 10.1124/jpet.102.044628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
382 Calléja C, Bigot K, Eeckhoutte C, Sibille P, Boulard C, Galtier P. Comparison of hepatic and renal drug-metabolising enzyme activities in sheep given single or two-fold challenge infections with Fasciola hepatica. International Journal for Parasitology 2000;30:953-8. [DOI: 10.1016/s0020-7519(00)00070-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
383 Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opinion on Drug Delivery 2015;12:1121-33. [DOI: 10.1517/17425247.2015.999038] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 11.5] [Reference Citation Analysis]
384 Kaur P, Chamberlin AR, Poulos TL, Sevrioukova IF. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model. J Med Chem 2016;59:4210-20. [PMID: 26371436 DOI: 10.1021/acs.jmedchem.5b01146] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
385 Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-9. [PMID: 12695340 DOI: 10.1124/dmd.31.5.533] [Cited by in Crossref: 185] [Cited by in F6Publishing: 159] [Article Influence: 10.3] [Reference Citation Analysis]
386 Saaristo M, Wong BBM, Mincarelli L, Craig A, Johnstone CP, Allinson M, Lindström K, Craft JA. Characterisation of the transcriptome of male and female wild-type guppy brains with RNA-Seq and consequences of exposure to the pharmaceutical pollutant, 17α-ethinyl estradiol. Aquat Toxicol 2017;186:28-39. [PMID: 28246045 DOI: 10.1016/j.aquatox.2017.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
387 Wei Y, Tang C, Sant V, Li S, Poloyac SM, Xie W. A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? Curr Pharmacol Rep 2016;2:187-92. [PMID: 27795941 DOI: 10.1007/s40495-016-0062-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
388 Wang X, Lee WY, Zhou X, Or PM, Yeung JH. A pharmacodynamic–pharmacokinetic (PD–PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat. Phytomedicine 2010;17:876-83. [DOI: 10.1016/j.phymed.2010.05.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
389 Pondugula SR, Flannery PC, Abbott KL, Coleman ES, Mani S, Samuel T, Xie W. Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. Toxicol Lett 2015;232:580-9. [PMID: 25542144 DOI: 10.1016/j.toxlet.2014.12.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
390 Vermaas JV, Baylon JL, Arcario MJ, Muller MP, Wu Z, Pogorelov TV, Tajkhorshid E. Efficient Exploration of Membrane-Associated Phenomena at Atomic Resolution. J Membr Biol 2015;248:563-82. [PMID: 25998378 DOI: 10.1007/s00232-015-9806-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
391 Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H. Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers. The Journal of Clinical Pharmacology 2009;49:568-73. [DOI: 10.1177/0091270009332435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
392 Feng S, Wu J, Qiu WL, Yang L, Deng X, Zhou Y, Chen Y, Li X, Yu L, Li H, Xu ZR, Xiao Y, Ren X, Zhang L, Wang C, Sun Z, Wang J, Ding X, Chen Y, Gadue P, Pan G, Ogawa M, Ogawa S, Na J, Zhang P, Hui L, Yin H, Chen L, Xu CR, Cheng X. Large-scale Generation of Functional and Transplantable Hepatocytes and Cholangiocytes from Human Endoderm Stem Cells. Cell Rep 2020;33:108455. [PMID: 33296648 DOI: 10.1016/j.celrep.2020.108455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
393 Akiyama TE, Gonzalez FJ. Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim Biophys Acta 2003;1619:223-34. [PMID: 12573481 DOI: 10.1016/s0304-4165(02)00480-4] [Cited by in Crossref: 88] [Cited by in F6Publishing: 19] [Article Influence: 4.9] [Reference Citation Analysis]
394 Perdomo VG, Rigalli JP, Villanueva SS, Ruiz ML, Luquita MG, Echenique CG, Catania VA. Modulation of biotransformation systems and ABC transporters by benznidazole in rats. Antimicrob Agents Chemother 2013;57:4894-902. [PMID: 23877690 DOI: 10.1128/AAC.02531-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
395 Zhao T, He Y, Wang J, Ding K, Wang C, Wang Z. Inhibition of Human Cytochrome P450 Enzymes 3A4 and 2D6 by β-Carboline Alkaloids, Harmine Derivatives: INHIBITION ON CYP 3A4 AND 2D6 BY B-CARBOLINE ALKALOIDS. Phytother Res 2011;25:1671-7. [DOI: 10.1002/ptr.3458] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
396 Fu GH, Yang XL, Zhang HX, Yu WJ, Hu K. Effects of cytochrome P450 1A substrate (difloxacin) on enzyme gene expression and pharmacokinetics in crucian carp (hybridized Prussian carp). Environmental Toxicology and Pharmacology 2011;31:307-13. [DOI: 10.1016/j.etap.2010.11.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
397 van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-92. [PMID: 17975676 DOI: 10.1172/JCI33435] [Cited by in Crossref: 177] [Cited by in F6Publishing: 49] [Article Influence: 13.6] [Reference Citation Analysis]
398 Ashour ML, Youssef FS, Gad HA, Wink M. Inhibition of Cytochrome P450 (CYP3A4) Activity by Extracts from 57 Plants Used in Traditional Chinese Medicine (TCM). Pharmacogn Mag 2017;13:300-8. [PMID: 28539725 DOI: 10.4103/0973-1296.204561] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
399 Takahashi K, Uejima E, Morisaki T, Takahashi K, Kurokawa N, Azuma J. In vitro inhibitory effects of Kampo medicines on metabolic reactions catalyzed by human liver microsomes: Influence of CYP activities by Kampo medicines. Journal of Clinical Pharmacy and Therapeutics 2003;28:319-27. [DOI: 10.1046/j.1365-2710.2003.00500.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
400 Deng S, Wang C, Zhang W, Gao W, Fan A, Zhang Q, Zhang Y, Liu Q, Li N, Liu Q, Zhao J, Li C, Wen X, Zhao D, Chen X. Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2. Xenobiotica 2013;44:583-90. [DOI: 10.3109/00498254.2013.870364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
401 Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P 450 enzyme identification, inhibition, and induction studies. Xenobiotica 2010;40:721-9. [DOI: 10.3109/00498254.2010.512670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
402 Miyamoto H, Matsueda S, Moritsuka A, Shimokawa K, Hirata H, Nakashima M, Sasaki H, Fumoto S, Nishida K. Evaluation of hypothermia on the in vitro metabolism and binding and in vivo disposition of midazolam in rats. Biopharm Drug Dispos 2015;36:481-9. [PMID: 26037413 DOI: 10.1002/bdd.1960] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
403 Agüeros M, Espuelas S, Esparza I, Calleja P, Peñuelas I, Ponchel G, Irache JM. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. Expert Opinion on Drug Delivery 2011;8:721-34. [DOI: 10.1517/17425247.2011.572069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
404 Ducharme J, Polic V, Auclair K. A Covalently Attached Progesterone Molecule Outcompetes the Binding of Free Progesterone at an Allosteric Site of Cytochrome P450 3A4. Bioconjugate Chem 2019;30:1629-35. [DOI: 10.1021/acs.bioconjchem.9b00248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
405 Schumacher SD, Jose J. Expression of active human P450 3A4 on the cell surface of Escherichia coli by Autodisplay. Journal of Biotechnology 2012;161:113-20. [DOI: 10.1016/j.jbiotec.2012.01.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
406 Yang Z, Rodrigues AD. Does the Long Plasma Half-Life of 4β-Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric? The Journal of Clinical Pharmacology 2010;50:1330-8. [DOI: 10.1177/0091270009360041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
407 Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O'Donoghue D, O'Sullivan M, O'Morain C, Mahmud N, Wikström AC, Kelleher D, McManus R. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006;130:341-8; quiz 592. [PMID: 16472590 DOI: 10.1053/j.gastro.2005.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 123] [Article Influence: 8.2] [Reference Citation Analysis]
408 Hegelund T, Celander MC. Hepatic versus extrahepatic expression of CYP3A30 and CYP3A56 in adult killifish (Fundulus heteroclitus). Aquat Toxicol 2003;64:277-91. [PMID: 12842592 DOI: 10.1016/s0166-445x(03)00057-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
409 Meucci V, Arukwe A. The xenoestrogen 4-nonylphenol modulates hepatic gene expression of pregnane X receptor, aryl hydrocarbon receptor, CYP3A and CYP1A1 in juvenile Atlantic salmon (Salmo salar). Comp Biochem Physiol C Toxicol Pharmacol 2006;142:142-50. [PMID: 16406821 DOI: 10.1016/j.cbpc.2005.11.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
410 Braun A, Hämmerle S, Suda K, Rothen-rutishauser B, Günthert M, Krämer SD, Wunderli-allenspach H. Cell cultures as tools in biopharmacy. European Journal of Pharmaceutical Sciences 2000;11:S51-60. [DOI: 10.1016/s0928-0987(00)00164-0] [Cited by in Crossref: 103] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
411 Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 2009;7:e001. [PMID: 19240808 DOI: 10.1621/nrs.07001] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
412 Hasselberg L, Grøsvik BE, Goksøyr A, Celander MC. Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus morhua). Comp Hepatol 2005;4:2. [PMID: 15701172 DOI: 10.1186/1476-5926-4-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
413 Zhang Y, Lin H. Quantum tunneling in testosterone 6beta-hydroxylation by cytochrome P450: reaction dynamics calculations employing multiconfiguration molecular-mechanical potential energy surfaces. J Phys Chem A 2009;113:11501-8. [PMID: 19480428 DOI: 10.1021/jp901850c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
414 Ueno T, Takahashi S, Nakamura T, Tanaka Y, Hori H, Mizoi K, Ogihara T. Evaluation system for cell-permeable CYP3A4 inhibitory activity using 1α,25-dihydroxy-vitamin D3-induced intestinal cell lines. Xenobiotica 2021;51:771-7. [PMID: 33947307 DOI: 10.1080/00498254.2021.1925375] [Reference Citation Analysis]
415 Qiao E, Ji M, Wu J, Ma R, Zhang X, He Y, Zha Q, Song X, Zhu LW, Tang J. Expression of the PXR gene in various types of cancer and drug resistance. Oncol Lett 2013;5:1093-100. [PMID: 23599746 DOI: 10.3892/ol.2013.1149] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
416 Ge G, Ning J, Hu L, Dai Z, Hou J, Cao Y, Yu Z, Ai C, Gu J, Ma X, Yang L. A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications. Chem Commun 2013;49:9779. [DOI: 10.1039/c3cc45250f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
417 Das A, Grinkova YV, Sligar SG. Redox potential control by drug binding to cytochrome P450 3A4. J Am Chem Soc 2007;129:13778-9. [PMID: 17948999 DOI: 10.1021/ja074864x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
418 Kourylko O, Fradette C, Arcand M, du Souich P. MODULATION OF CYP1A2 AND CYP3A6 CATALYTIC ACTIVITIES BY SERUM FROM RABBITS WITH A TURPENTINE-INDUCED INFLAMMATORY REACTION AND INTERLEUKIN 6. Drug Metab Dispos 2005;34:27-35. [DOI: 10.1124/dmd.105.006528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
419 Raunio H, Rautio A, Gullstén H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001;52:357-63. [PMID: 11678779 DOI: 10.1046/j.0306-5251.2001.01500.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 5.6] [Reference Citation Analysis]
420 Fang P, Tang PF, Xu RA, Zheng X, Wen J, Bao SS, Cai JP, Hu GX. Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Des Devel Ther 2017;11:3503-10. [PMID: 29263648 DOI: 10.2147/DDDT.S152366] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
421 Dunn AR, Dmochowski IJ, Bilwes AM, Gray HB, Crane BR. Probing the open state of cytochrome P450cam with ruthenium-linker substrates. Proc Natl Acad Sci U S A 2001;98:12420-5. [PMID: 11606730 DOI: 10.1073/pnas.221297998] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 4.0] [Reference Citation Analysis]
422 Dhir A, Zolkowska D, Rogawski MA. Seizure protection by intrapulmonary delivery of midazolam in mice. Neuropharmacology 2013;73:425-31. [PMID: 23774136 DOI: 10.1016/j.neuropharm.2013.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
423 Selvi A, Das D, Das N. Potentiality of yeast Candida sp. SMN04 for degradation of cefdinir, a cephalosporin antibiotic: kinetics, enzyme analysis and biodegradation pathway. Environmental Technology 2015;36:3112-24. [DOI: 10.1080/09593330.2015.1054318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
424 Qian CQ, Zhao KJ, Chen Y, Liu L, Liu XD. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover. Eur J Pharm Sci 2019;134:194-204. [PMID: 31047967 DOI: 10.1016/j.ejps.2019.04.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
425 van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 2008;73:1029-36. [PMID: 18156313 DOI: 10.1124/mol.107.043869] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
426 Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine. Xenobiotica 2009;39:140-7. [DOI: 10.1080/00498250802617746] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
427 Berntssen M, Ørnsrud R, Hamre K, Lie K. Polyaromatic hydrocarbons in aquafeeds, source, effects and potential implications for vitamin status of farmed fish species: a review. Aquacult Nutr 2015;21:257-73. [DOI: 10.1111/anu.12309] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
428 Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4:413-424. [PMID: 18524030 DOI: 10.1517/17425255.4.4.413] [Cited by in Crossref: 102] [Cited by in F6Publishing: 90] [Article Influence: 7.8] [Reference Citation Analysis]
429 Mortensen AS, Arukwe A. Effects of 17alpha-ethynylestradiol on hormonal responses and xenobiotic biotransformation system of Atlantic salmon (Salmo salar). Aquat Toxicol 2007;85:113-23. [PMID: 17875331 DOI: 10.1016/j.aquatox.2007.08.004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
430 Chen M, Lu W, Lu Y, Kang L, Zhao H, Lin ZJ, Wang W, Fraier D, Ottaviani G. An ultra-sensitive LC–MS/MS method to determine midazolam levels in human plasma: development, validation and application to a clinical study. Bioanalysis 2017;9:297-312. [DOI: 10.4155/bio-2016-0191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
431 Karakurt S. Modulatory effects of rutin on the expression of cytochrome P450s and antioxidant enzymes in human hepatoma cells. Acta Pharm 2016;66:491-502. [PMID: 27749250 DOI: 10.1515/acph-2016-0046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
432 Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104. [PMID: 14574440 DOI: 10.1007/s00210-003-0819-z] [Cited by in Crossref: 210] [Cited by in F6Publishing: 181] [Article Influence: 11.7] [Reference Citation Analysis]
433 Hamura R, Furukawa K, Sakamoto T, Gocho T, Shiba H, Yanaga K. Eradication of Helicobacter pylori in a Living Donor Liver Transplant Recipient With Immunosuppressive Therapy of Cyclosporine A: A Case Report. Transplantation Proceedings 2019;51:1006-7. [DOI: 10.1016/j.transproceed.2019.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
434 Aswathy L, Jisha RS, Masand VH, Gajbhiye JM, Shibi IG. Computational strategies to explore antimalarial thiazine alkaloid lead compounds based on an Australian marine sponge Plakortis Lita. J Biomol Struct Dyn 2017;35:2407-29. [PMID: 27494993 DOI: 10.1080/07391102.2016.1220870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
435 Barnaba C, Gentry K, Sumangala N, Ramamoorthy A. The catalytic function of cytochrome P450 is entwined with its membrane-bound nature. F1000Res 2017;6:662. [PMID: 28529725 DOI: 10.12688/f1000research.11015.1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
436 Neve EPA, Artursson P, Ingelman-sundberg M, Karlgren M. An Integrated in Vitro Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux. Mol Pharmaceutics 2013;10:3152-63. [DOI: 10.1021/mp400202d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
437 Sultana H, Komai M, Shirakawa H. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients 2021;13:2515. [PMID: 34444675 DOI: 10.3390/nu13082515] [Reference Citation Analysis]
438 Guruge KS, Yamanaka N, Sonobe M, Fujizono W, Yoshioka M, Akiba M, Yamamoto T, Joshua DI, Balakrishna K, Yamashita N, Kannan K, Tsutsui T. Source-Related Effects of Wastewater on Transcription Factor (AhR, CAR and PXR)-Mediated Induction of Gene Expression in Cultured Rat Hepatocytes and Their Association with the Prevalence of Antimicrobial-Resistant Escherichia coli. PLoS One 2015;10:e0138391. [PMID: 26381891 DOI: 10.1371/journal.pone.0138391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
439 Anger GJ, Piquette-miller M. Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes. Drug Metab Dispos 2011;39:1850-9. [DOI: 10.1124/dmd.111.040626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
440 Holy P, Kloudova A, Soucek P. Importance of genetic background of oxysterol signaling in cancer. Biochimie 2018;153:109-38. [DOI: 10.1016/j.biochi.2018.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
441 Ribonnet L, van der Heiden E, Nobels I, Chaumont A, Remacle AS, De Saeger S, Schneider YJ, Scippo ML, Blust R, Pussemier L, Larondelle Y. Potential of an in vitro toolbox combined with exposure data as a first step for the risk assessment of dietary chemical contaminants. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011;28:1136-58. [PMID: 21762035 DOI: 10.1080/19440049.2011.584069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
442 Wang A, Yu BN, Luo CH, Tan ZR, Zhou G, Wang LS, Zhang W, Li Z, Liu J, Zhou HH. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005;60:843-8. [PMID: 15650881 DOI: 10.1007/s00228-004-0848-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
443 Bozina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009;60:217-42. [PMID: 19581216 DOI: 10.2478/10004-1254-60-2009-1885] [Cited by in Crossref: 104] [Cited by in F6Publishing: 81] [Article Influence: 8.7] [Reference Citation Analysis]
444 Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001;11:111-21. [PMID: 11266076 DOI: 10.1097/00008571-200103000-00002] [Cited by in Crossref: 153] [Cited by in F6Publishing: 145] [Article Influence: 7.7] [Reference Citation Analysis]
445 Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585-1592. [PMID: 15523087 DOI: 10.1093/jnci/djh298] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
446 Ning J, Wang W, Ge G, Chu P, Long F, Yang Y, Peng Y, Feng L, Ma X, James TD. Target Enzyme‐Activated Two‐Photon Fluorescent Probes: A Case Study of CYP3A4 Using a Two‐Dimensional Design Strategy. Angew Chem 2019;131:10064-8. [DOI: 10.1002/ange.201903683] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
447 Zhou D, Afzelius L, Grimm SW, Andersson TB, Zauhar RJ, Zamora I. COMPARISON OF METHODS FOR THE PREDICTION OF THE METABOLIC SITES FOR CYP3A4-MEDIATED METABOLIC REACTIONS. Drug Metab Dispos 2006;34:976-83. [DOI: 10.1124/dmd.105.008631] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
448 Kojima M, Degawa M. Sex differences in constitutive mRNA levels of CYP2B22, CYP2C33, CYP2C49, CYP3A22, CYP3A29 and CYP3A46 in the pig liver: Comparison between Meishan and Landrace pigs. Drug Metabolism and Pharmacokinetics 2016;31:185-92. [DOI: 10.1016/j.dmpk.2016.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
449 Lee CM, Pohl J, Morgan ET. Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 2009;37:865-72. [PMID: 19171675 DOI: 10.1124/dmd.108.026187] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
450 Masi CM, Olopade OI. Racial and Ethnic Disparities in Breast Cancer: A Multilevel Perspective. Medical Clinics of North America 2005;89:753-70. [DOI: 10.1016/j.mcna.2005.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
451 Castellino S, O'mara M, Koch K, Borts DJ, Bowers GD, Maclauchlin C. Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity. Drug Metab Dispos 2011;40:139-50. [DOI: 10.1124/dmd.111.040949] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
452 Li Y, Yu L, Zhu Z, Dai J, Mai B, Wu J, Wang J. Accumulation and effects of 90-day oral exposure to Dechlorane Plus in quail (Coturnix coturnix). Environ Toxicol Chem 2013;32:1649-54. [PMID: 23440862 DOI: 10.1002/etc.2202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
453 Nowakowski-gashaw I, Mrozikiewicz PM, Roots I, Brockmöller J. Rapid Quantification of CYP3A4 Expression in Human Leukocytes by Real-Time Reverse Transcription-PCR. Clinical Chemistry 2002;48:366-70. [DOI: 10.1093/clinchem/48.2.366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
454 Liu C, Peck K, Huang J, Lin M, Wang C, Hsu W, Wang H, Lee H, Lai M. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005;6:731-47. [DOI: 10.2217/14622416.6.7.731] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
455 Reyes-Hernández OD, Arteaga-Illán G, Elizondo G. Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population. Clin Genet 2004;66:166-8. [PMID: 15253768 DOI: 10.1111/j.1399-0004.2004.00286.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
456 Wang YM, Lin W, Chai SC, Wu J, Ong SS, Schuetz EG, Chen T. Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol Appl Pharmacol 2013;272:96-107. [PMID: 23707768 DOI: 10.1016/j.taap.2013.05.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
457 Das A, Zhao J, Schatz GC, Sligar SG, Van Duyne RP. Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. Anal Chem 2009;81:3754-9. [PMID: 19364136 DOI: 10.1021/ac802612z] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 8.2] [Reference Citation Analysis]
458 Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Archives of Biochemistry and Biophysics 2005;433:387-96. [DOI: 10.1016/j.abb.2004.08.030] [Cited by in Crossref: 123] [Cited by in F6Publishing: 114] [Article Influence: 7.7] [Reference Citation Analysis]
459 Alqahtani S, Mohamed LA, Kaddoumi A. Experimental models for predicting drug absorption and metabolism. Expert Opinion on Drug Metabolism & Toxicology 2013;9:1241-54. [DOI: 10.1517/17425255.2013.802772] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
460 Xu Y, Ding L, Wang Z, Wang Y, Sun L. Virtual Screening of Cablin Patchouli Herb as a Treatment for Heat Stress: A Study Based on Network Pharmacology, Molecular Docking, and Experimental Verification. Evid Based Complement Alternat Med 2021;2021:8057587. [PMID: 33777163 DOI: 10.1155/2021/8057587] [Reference Citation Analysis]
461 Flaman AS, Gravel C, Hashem AM, Tocchi M, Li X. The effect of interferon-α on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol 2011;253:130-6. [PMID: 21466820 DOI: 10.1016/j.taap.2011.03.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
462 Chianese G, Sepe V, Limongelli V, Renga B, D'Amore C, Zampella A, Taglialatela-Scafati O, Fiorucci S. Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists. Steroids 2014;83:80-5. [PMID: 24582706 DOI: 10.1016/j.steroids.2014.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
463 Monroe KR, Murphy SP, Kolonel LN, Pike MC. Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. Br J Cancer. 2007;97:440-445. [PMID: 17622247 DOI: 10.1038/sj.bjc.6603880] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
464 Müller CS, Knehans T, Davydov DR, Bounds PL, von Mandach U, Halpert JR, Caflisch A, Koppenol WH. Concurrent cooperativity and substrate inhibition in the epoxidation of carbamazepine by cytochrome P450 3A4 active site mutants inspired by molecular dynamics simulations. Biochemistry 2015;54:711-21. [PMID: 25545162 DOI: 10.1021/bi5011656] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
465 Teixeira VH, Ribeiro V, Martel PJ. Analysis of binding modes of ligands to multiple conformations of CYP3A4. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2010;1804:2036-45. [DOI: 10.1016/j.bbapap.2010.06.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
466 Akiyoshi T, Saito T, Murase S, Miyazaki M, Murayama N, Yamazaki H, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab Dispos 2011;39:724-8. [PMID: 21212239 DOI: 10.1124/dmd.110.036780] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
467 Wei X, Kenny JR, Dickmann L, Maciuca R, Looney C, Tang MT. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol. 2016;56:693-704. [PMID: 26412221 DOI: 10.1002/jcph.649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
468 Dhawan K, Sharma A. Restoration of chronic-Delta 9-THC-induced decline in sexuality in male rats by a novel benzoflavone moiety from Passiflora incarnata Linn. Br J Pharmacol 2003;138:117-20. [PMID: 12522080 DOI: 10.1038/sj.bjp.0705015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
469 Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 2007;117:3173-6. [PMID: 17975661 DOI: 10.1172/JCI34007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
470 Bulutoglu B, Mert S, Rey-Bedón C, Deng SL, Yarmush ML, Usta OB. Rapid maturation of the hepatic cell line Huh7 via CDK inhibition for PXR dependent CYP450 metabolism and induction. Sci Rep 2019;9:15848. [PMID: 31676845 DOI: 10.1038/s41598-019-52174-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
471 Gnedenko O, Yablokov E, Usanov S, Mukha D, Sergeev G, Bulko T, Kuzikov A, Moskaleva N, Shumyantseva V, Ivanov A, Archakov A. SPR and electrochemical analyses of interactions between CYP3A4 or 3A5 and cytochrome b5. Chemical Physics Letters 2014;593:40-4. [DOI: 10.1016/j.cplett.2013.12.041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
472 Pasqua M, Di Gesù R, Chinnici CM, Conaldi PG, Francipane MG. Generation of Hepatobiliary Cell Lineages from Human Induced Pluripotent Stem Cells: Applications in Disease Modeling and Drug Screening. Int J Mol Sci 2021;22:8227. [PMID: 34360991 DOI: 10.3390/ijms22158227] [Reference Citation Analysis]
473 Howell MC, Green R, Khalil R, Foran E, Quarni W, Nair R, Stevens S, Grinchuk A, Hanna A, Mohapatra S, Mohapatra S. Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis. FASEB Bioadv 2020;2:90-105. [PMID: 32123859 DOI: 10.1096/fba.2019-00081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
474 Shiran M, Gregory A, Rostami-hodjegan A, Tucker G, Lennard M. Determination of midazolam and 1′-hydroxymidazolam by liquid chromatography–mass spectrometry in plasma of patients undergoing methadone maintenance treatment. Journal of Chromatography B 2003;783:303-7. [DOI: 10.1016/s1570-0232(02)00673-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
475 Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, Greenblatt DJ. Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies. The Journal of Clinical Pharmacology 2001;41:1043-54. [DOI: 10.1177/00912700122012634] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
476 Podszun M, Frank J. Vitamin E-drug interactions: molecular basis and clinical relevance. Nutr Res Rev. 2014;27:215-231. [PMID: 25225959 DOI: 10.1017/s0954422414000146] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
477 van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 2010;160:1224-33. [PMID: 20590614 DOI: 10.1111/j.1476-5381.2010.00759.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
478 Marsch GA, Carlson BT, Guengerich FP. 7,8-benzoflavone binding to human cytochrome P450 3A4 reveals complex fluorescence quenching, suggesting binding at multiple protein sites. J Biomol Struct Dyn 2018;36:841-60. [PMID: 28278026 DOI: 10.1080/07391102.2017.1301270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
479 Joußen N, Heckel DG, Haas M, Schuphan I, Schmidt B. Metabolism of imidacloprid and DDT by P450 CYP6G1 expressed in cell cultures ofNicotiana tabacum suggests detoxification of these insecticides inCyp6g1-overexpressing strains ofDrosophila melanogaster, leading to resistance. Pest Manag Sci 2008;64:65-73. [DOI: 10.1002/ps.1472] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 9.1] [Reference Citation Analysis]
480 Xu Y, Li P, Zhang X, Wang J, Gu D, Wang Y. In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7. Afr Health Sci 2014;14:564-9. [PMID: 25352873 DOI: 10.4314/ahs.v14i3.10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
481 Nagayoshi H, Murayama N, Kakimoto K, Tsujino M, Takenaka S, Katahira J, Lim YR, Kim D, Yamazaki H, Komori M, Guengerich FP, Shimada T. Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chem Res Toxicol 2019;32:1268-80. [PMID: 30964977 DOI: 10.1021/acs.chemrestox.9b00078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
482 Yamada M, Utoh R, Ohashi K, Tatsumi K, Yamato M, Okano T, Seki M. Controlled formation of heterotypic hepatic micro-organoids in anisotropic hydrogel microfibers for long-term preservation of liver-specific functions. Biomaterials 2012;33:8304-15. [PMID: 22906609 DOI: 10.1016/j.biomaterials.2012.07.068] [Cited by in Crossref: 171] [Cited by in F6Publishing: 136] [Article Influence: 19.0] [Reference Citation Analysis]
483 Treuheit NA, Redhair M, Kwon H, McClary WD, Guttman M, Sumida JP, Atkins WM. Membrane Interactions, Ligand-Dependent Dynamics, and Stability of Cytochrome P4503A4 in Lipid Nanodiscs. Biochemistry 2016;55:1058-69. [PMID: 26814638 DOI: 10.1021/acs.biochem.5b01313] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
484 van den Bosch HM, Bünger M, de Groot PJ, van der Meijde J, Hooiveld GJ, Müller M. Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting. BMC Genomics 2007;8:267. [PMID: 17683626 DOI: 10.1186/1471-2164-8-267] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
485 Hashem HM, Mahrouse MA. In vitro metabolism study of a novel P38 kinase inhibitor: in silico predictions, structure elucidation using MS/MS-I. Future Medicinal Chemistry 2018;10:201-20. [DOI: 10.4155/fmc-2017-0126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
486 Woodland C, Huang TT, Gryz E, Bendayan R, Fawcett JP. Expression, Activity and Regulation of CYP3A in Human and Rodent Brain. Drug Metabolism Reviews 2008;40:149-68. [DOI: 10.1080/03602530701836712] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
487 Sepe V, Ummarino R, D'auria MV, Renga B, Fiorucci S, Zampella A. The First Total Synthesis of Solomonsterol B, a Marine Pregnane X Receptor Agonist. Eur J Org Chem 2012;2012:5187-94. [DOI: 10.1002/ejoc.201200619] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
488 Nebert DW, Dalton TP, Stuart GW, Carvan MJ 3rd. "Gene-swap knock-in" cassette in mice to study allelic differences in human genes. Ann N Y Acad Sci 2000;919:148-70. [PMID: 11083106 DOI: 10.1111/j.1749-6632.2000.tb06876.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
489 Oh WS, Kim DN, Jung J, Cho K, No KT. New Combined Model for the Prediction of Regioselectivity in Cytochrome P450/3A4 Mediated Metabolism. J Chem Inf Model 2008;48:591-601. [DOI: 10.1021/ci7003576] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
490 Akiyama N, Inui N, Mori K, Nakamura Y, Hayakawa H, Tanaka S, Uchida S, Namiki N, Watanabe H, Suda T. Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex. J Thorac Dis 2019;11:3814-21. [PMID: 31656654 DOI: 10.21037/jtd.2019.09.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
491 Wang Y, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. Br J Pharmacol 2020;177:3060-74. [PMID: 32087611 DOI: 10.1111/bph.15034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
492 Singh D, Cho WC, Upadhyay G. Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview. Front Physiol 2015;6:363. [PMID: 26858648 DOI: 10.3389/fphys.2015.00363] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
493 Mak PJ, Denisov IG, Grinkova YV, Sligar SG, Kincaid JR. Defining CYP3A4 structural responses to substrate binding. Raman spectroscopic studies of a nanodisc-incorporated mammalian cytochrome P450. J Am Chem Soc 2011;133:1357-66. [PMID: 21207936 DOI: 10.1021/ja105869p] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
494 Chan TS, Scaringella YS, Raymond K, Taub ME. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture. Drug Metab Dispos 2020;48:690-7. [PMID: 32503882 DOI: 10.1124/dmd.120.090951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
495 Pearson J, Dahal UP, Rock D, Peng CC, Schenk JO, Joswig-Jones C, Jones JP. The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds: evidence supporting direct reduction. Arch Biochem Biophys 2011;511:69-79. [PMID: 21530484 DOI: 10.1016/j.abb.2011.04.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
496 Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye (Lond) 2019;33:1035-43. [PMID: 30824822 DOI: 10.1038/s41433-019-0381-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
497 Je YT, Sim WC, Kim DG, Jung BH, Shin HS, Lee BH. Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism. Arch Toxicol 2015;89:579-89. [PMID: 24853400 DOI: 10.1007/s00204-014-1268-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
498 Christen V, Caminada D, Arand M, Fent K. Identification of a CYP3A form (CYP3A126) in fathead minnow (Pimephales promelas) and characterisation of putative CYP3A enzyme activity. Anal Bioanal Chem 2010;396:585-95. [PMID: 19898817 DOI: 10.1007/s00216-009-3251-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
499 Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-88. [DOI: 10.1002/hep.1840380424] [Cited by in Crossref: 210] [Cited by in F6Publishing: 122] [Article Influence: 11.7] [Reference Citation Analysis]
500 Müller MJ, Stokes CS, Lammert F, Volmer DA. Chemotyping the distribution of vitamin D metabolites in human serum. Sci Rep 2016;6:21080. [PMID: 26864540 DOI: 10.1038/srep21080] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
501 Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, Krasinskas A, Chalasani N, Mattar SG. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg. 2010;251:1041-1048. [PMID: 20485142 DOI: 10.1097/sla.0b013e3181dbb572] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
502 Vaccaro E, Salvetti A, Del Carratore R, Nencioni S, Longo V, Gervasi PG. Cloning, tissue expression, and inducibility of CYP 3A79 from sea bass (Dicentrarchus labrax). J Biochem Mol Toxicol 2007;21:32-40. [PMID: 17366542 DOI: 10.1002/jbt.20153] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
503 Lewis D, Dickins M. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 2002;170:45-53. [DOI: 10.1016/s0300-483x(01)00524-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
504 Zhu BT, Lee AJ. NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids. 2005;70:225-244. [PMID: 15784278 DOI: 10.1016/j.steroids.2005.01.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
505 Schiffman SS, Rother KI. Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev 2013;16:399-451. [PMID: 24219506 DOI: 10.1080/10937404.2013.842523] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
506 Isin EM, Guengerich FP. Multiple Sequential Steps Involved in the Binding of Inhibitors to Cytochrome P450 3A4. Journal of Biological Chemistry 2007;282:6863-74. [DOI: 10.1074/jbc.m610346200] [Cited by in Crossref: 62] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
507 Shaik S, Cohen S, Wang Y, Chen H, Kumar D, Thiel W. P450 Enzymes: Their Structure, Reactivity, and Selectivity—Modeled by QM/MM Calculations. Chem Rev 2010;110:949-1017. [DOI: 10.1021/cr900121s] [Cited by in Crossref: 721] [Cited by in F6Publishing: 615] [Article Influence: 60.1] [Reference Citation Analysis]
508 Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, Strobel HW, Ravindranath V. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 2008;3:e2337. [PMID: 18545703 DOI: 10.1371/journal.pone.0002337] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
509 Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23:687-702. [PMID: 12372848 DOI: 10.1210/er.2001-0038] [Cited by in Crossref: 609] [Cited by in F6Publishing: 572] [Article Influence: 33.8] [Reference Citation Analysis]
510 Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 2015;:CD011841. [PMID: 26691378 DOI: 10.1002/14651858.CD011841.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
511 Schofield J, Derdau V, Atzrodt J, Zane P, Guo Z, van Horn R, Czepczor V, Stoltz A, Pardon M. Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638. Bioorganic & Medicinal Chemistry 2015;23:3831-42. [DOI: 10.1016/j.bmc.2015.03.065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
512 Klümpen H, Samer CF, Mathijssen RH, Schellens JH, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treatment Reviews 2011;37:251-60. [DOI: 10.1016/j.ctrv.2010.08.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
513 van Herwaarden AE, van Waterschoot RA, Schinkel AH. How important is intestinal cytochrome P450 3A metabolism? Trends in Pharmacological Sciences 2009;30:223-7. [DOI: 10.1016/j.tips.2009.02.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
514 Atkins WM. Implications of the allosteric kinetics of cytochrome P450s. Drug Discovery Today 2004;9:478-84. [DOI: 10.1016/s1359-6446(04)03072-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
515 Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486-1489. [PMID: 12490779 DOI: 10.1097/00007890-200212150-00002] [Cited by in Crossref: 243] [Cited by in F6Publishing: 229] [Article Influence: 13.5] [Reference Citation Analysis]
516 Fallacara AL, Zamperini C, Podolski-Renić A, Dinić J, Stanković T, Stepanović M, Mancini A, Rango E, Iovenitti G, Molinari A, Bugli F, Sanguinetti M, Torelli R, Martini M, Maccari L, Valoti M, Dreassi E, Botta M, Pešić M, Schenone S. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. Cancers (Basel) 2019;11:E848. [PMID: 31248184 DOI: 10.3390/cancers11060848] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
517 Yamaguchi Y, Khan KK, He YA, He YQ, Halpert JR. TOPOLOGICAL CHANGES IN THE CYP3A4 ACTIVE SITE PROBED WITH PHENYLDIAZENE: EFFECT OF INTERACTION WITH NADPH-CYTOCHROME P450 REDUCTASE AND CYTOCHROME B5 AND OF SITE-DIRECTED MUTAGENESIS. Drug Metab Dispos 2004;32:155-61. [DOI: 10.1124/dmd.32.1.155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
518 Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54-58. [PMID: 22985909 DOI: 10.1016/j.jsbmb.2012.09.012] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
519 Ma RC, Chan WB, So WY, Tong PC, Chan JC, Chow CC. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. BMJ 2005;330:299-300. [PMID: 15695278 DOI: 10.1136/bmj.330.7486.299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
520 Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of Human Cytochrome P450s Involved in the Formation of All- trans -Retinoic Acid Principal Metabolites. Mol Pharmacol 2000;58:1341-8. [DOI: 10.1124/mol.58.6.1341] [Cited by in Crossref: 137] [Cited by in F6Publishing: 138] [Article Influence: 6.5] [Reference Citation Analysis]
521 Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemother Pharmacol 2020;85:899-906. [PMID: 32248324 DOI: 10.1007/s00280-020-04067-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
522 Akazawa Y, Kawaguchi H, Funahashi M, Watanabe Y, Yamaoka K, Hashida M, Takakura Y. Effect of Interferons on P‐Glycoprotein‐Mediated Rhodamine‐123 Efflux in Cultured Rat Hepatocytes. Journal of Pharmaceutical Sciences 2002;91:2110-5. [DOI: 10.1002/jps.10199] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
523 Ulvestad M, Nordell P, Asplund A, Rehnström M, Jacobsson S, Holmgren G, Davidson L, Brolén G, Edsbagge J, Björquist P, Küppers-Munther B, Andersson TB. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol 2013;86:691-702. [PMID: 23856292 DOI: 10.1016/j.bcp.2013.06.029] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
524 Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ. Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 2005;146:2911-9. [PMID: 15817670 DOI: 10.1210/en.2004-1248] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
525 Smith M, Madec S, Pawtowski A, Coton E, Hymery N. Individual and combined toxicological effects of deoxynivalenol and zearalenone on human hepatocytes in in vitro chronic exposure conditions. Toxicology Letters 2017;280:238-46. [DOI: 10.1016/j.toxlet.2017.08.080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
526 Breslin S, O'Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget. 2016;7:45745-45756. [PMID: 27304190 DOI: 10.18632/oncotarget.9935] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 40.7] [Reference Citation Analysis]
527 Nair PM, Park SY, Choi J. Characterization and expression of cytochrome p450 cDNA (CYP9AT2) in Chironomus riparius fourth instar larvae exposed to multiple xenobiotics. Environ Toxicol Pharmacol 2013;36:1133-40. [PMID: 24177577 DOI: 10.1016/j.etap.2013.08.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
528 Ard SG, Melko JJ, Ushakov VG, Johnson R, Fournier JA, Shuman NS, Guo H, Troe J, Viggiano AA. Activation of Methane by FeO + : Determining Reaction Pathways through Temperature-Dependent Kinetics and Statistical Modeling. J Phys Chem A 2014;118:2029-39. [DOI: 10.1021/jp5000705] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 5.9] [Reference Citation Analysis]
529 Fernando H, Halpert JR, Davydov DR. Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry 2006;45:4199-209. [PMID: 16566594 DOI: 10.1021/bi052491b] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
530 Balding PR, Porro CS, McLean KJ, Sutcliffe MJ, Maréchal JD, Munro AW, de Visser SP. How do azoles inhibit cytochrome P450 enzymes? A density functional study. J Phys Chem A 2008;112:12911-8. [PMID: 18563875 DOI: 10.1021/jp802087w] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
531 Patel RD, Hollingshead BD, Omiecinski CJ, Perdew GH. Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver. Hepatology 2007;46:209-18. [PMID: 17596880 DOI: 10.1002/hep.21671] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
532 Lee JS, Ward WO, Wolf DC, Allen JW, Mills C, DeVito MJ, Corton JC. Coordinated changes in xenobiotic metabolizing enzyme gene expression in aging male rats. Toxicol Sci 2008;106:263-83. [PMID: 18653662 DOI: 10.1093/toxsci/kfn144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
533 Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem Biophys Res Commun 2003;312:121-30. [PMID: 14630029 DOI: 10.1016/j.bbrc.2003.09.247] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
534 Qiu F, Hou X, Takahashi K, Chen L, Azuma J, Kang N. Andrographolide inhibits the expression and metabolic activity of cytochrome P450 3A4 in the modified Caco-2 cells. Journal of Ethnopharmacology 2012;141:709-13. [DOI: 10.1016/j.jep.2011.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
535 Kern F, Khatri Y, Litzenburger M, Bernhardt R. CYP267A1 and CYP267B1 from Sorangium cellulosum So ce56 are Highly Versatile Drug Metabolizers. Drug Metabolism and Disposition 2016;44:495-504. [DOI: 10.1124/dmd.115.068486] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
536 Esmaeili-Rad A, Khanjani S, Vaziri H, Kazemnejad S. Gene expression pattern of some classes of cytochrome P-450 and glutathione S-transferase enzymes in differentiated hepatocytes-like cells from menstrual blood stem cells. In Vitro Cell Dev Biol Anim 2015;51:530-8. [PMID: 25614436 DOI: 10.1007/s11626-014-9857-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
537 Denisov IG, Sligar SG. A novel type of allosteric regulation: functional cooperativity in monomeric proteins. Arch Biochem Biophys 2012;519:91-102. [PMID: 22245335 DOI: 10.1016/j.abb.2011.12.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
538 Chaturvedi S, Verma A, Saharan VA. Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement. Adv Pharm Bull 2020;10:524-41. [PMID: 33072532 DOI: 10.34172/apb.2020.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
539 Miyauchi Y, Nagata K, Yamazoe Y, Mackenzie PI, Yamada H, Ishii Y. Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region. Mol Pharmacol 2015;88:800-12. [PMID: 26243732 DOI: 10.1124/mol.115.098582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
540 Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007;292:G1114-22. [PMID: 17170021 DOI: 10.1152/ajpgi.00528.2006] [Cited by in Crossref: 142] [Cited by in F6Publishing: 145] [Article Influence: 9.5] [Reference Citation Analysis]
541 Grobbelaar M, Louw GE, Sampson SL, van Helden PD, Donald PR, Warren RM. Evolution of rifampicin treatment for tuberculosis. Infect Genet Evol 2019;74:103937. [PMID: 31247337 DOI: 10.1016/j.meegid.2019.103937] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
542 Ahn JH, Park WS, Jun MA, Shin MS, Kang SK, Kim KY, Rhee SD, Bae MA, Kim KR, Kim SG, Kim SY, Sohn SK, Kang NS, Lee JO, Lee DH, Cheon HG, Kim SS. Synthesis and biological evaluation of homopiperazine derivatives with β-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters 2008;18:6525-9. [DOI: 10.1016/j.bmcl.2008.10.076] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
543 Shin D, Seo H, Yang JY, Joo J, Im SH, Kim SS, Kim SK, Bae MA. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids. Int J Toxicol 2018;37:393-403. [DOI: 10.1177/1091581818780149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
544 Marathe PH, Rodrigues AD. Examination of CYP3A and P-Glycoprotein-Mediated Drug–Drug Interactions Using Animal Models. In: Zhou J, editor. Multi-Drug Resistance in Cancer. Totowa: Humana Press; 2010. pp. 385-403. [DOI: 10.1007/978-1-60761-416-6_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
545 Oleson L, von Moltke LL, Greenblatt DJ, Court MH. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 2010;40:146-62. [PMID: 20082578 DOI: 10.3109/00498250903420243] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
546 Emoto C, Nishida H, Hirai H, Iwasaki K. CYP3A4 and CYP3A5 catalyse the conversion of the N -methyl-D-aspartate (NMDA) antagonist CJ-036878 to two novel dimers. Xenobiotica 2010;37:1408-20. [DOI: 10.3109/00498250701658304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
547 Hirao H, Chuanprasit P, Cheong YY, Wang X. How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation? Chemistry 2013;19:7361-9. [PMID: 23592585 DOI: 10.1002/chem.201300689] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
548 Matsumoto T, Kushida H, Maruyama T, Nishimura H, Watanabe J, Maemura K, Kase Y. In vitro identification of human cytochrome P450 isoforms involved in the metabolism of Geissoschizine methyl ether, an active component of the traditional Japanese medicine Yokukansan. Xenobiotica 2016;46:325-34. [PMID: 26337900 DOI: 10.3109/00498254.2015.1076585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
549 Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A, Benetti A, Invernizzi P, Podda M. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2009;41:e8-e10. [PMID: 18294936 DOI: 10.1016/j.dld.2007.12.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
550 Liu CL, Lim YP, Hu ML. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 2012;10:242-57. [PMID: 22363234 DOI: 10.3390/md10010242] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
551 Rydberg P, Olsen L. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem 2012;7:1202-9. [PMID: 22593031 DOI: 10.1002/cmdc.201200160] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
552 Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochemical Pharmacology 2008;75:1426-37. [DOI: 10.1016/j.bcp.2007.11.012] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
553 Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interactions caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther. 2010;125:230-248. [PMID: 19951720 DOI: 10.1016/j.pharmthera.2009.10.011] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
554 Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 2006;46:41-64. [PMID: 16402898 DOI: 10.1146/annurev.pharmtox.45.120403.100007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 7.3] [Reference Citation Analysis]
555 Li W, Luo S, Smith HT, Tse FLS. Simultaneous determination of midazolam and 1′-hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry. Biomed Chromatogr 2007;21:841-51. [DOI: 10.1002/bmc.829] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
556 Mak PJ, Zhu Q, Kincaid JR. Using resonance Raman cross-section data to estimate the spin state populations of Cytochromes P450. J Raman Spectrosc 2013;44:1792-4. [PMID: 24443630 DOI: 10.1002/jrs.4401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
557 Cheung C, Yu A, Chen C, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ. Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice. J Pharmacol Exp Ther 2006;316:1328-34. [DOI: 10.1124/jpet.105.094367] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 4.2] [Reference Citation Analysis]
558 Liu Y, Wang J, Wei Y, Zhang H, Liu Y, Dai J. Molecular characterization of cytochrome P450 1A and 3A and the effects of perfluorooctanoic acid on their mRNA levels in rare minnow (Gobiocypris rarus) gills. Aquat Toxicol 2008;88:183-90. [PMID: 18508136 DOI: 10.1016/j.aquatox.2008.04.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
559 Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 2008;4:895-908. [PMID: 18624678 DOI: 10.1517/17425255.4.7.895] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 6.4] [Reference Citation Analysis]
560 Ince I, de Wildt SN, Wang C, Peeters MY, Burggraaf J, Jacqz-Aigrain E, van den Anker JN, Tibboel D, Danhof M, Knibbe CA. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clin Pharmacokinet 2013;52:555-65. [PMID: 23512668 DOI: 10.1007/s40262-013-0050-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
561 Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R. Quantification of granisetron in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry. Biomed Chromatogr 2006;20:888-97. [DOI: 10.1002/bmc.613] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
562 Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 2008;4:137-49. [PMID: 18248309 DOI: 10.1517/17425255.4.2.137] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
563 Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, Lee HS. Role of human cytochrome P450 3A4 in the metabolism of DA–8159, a new erectogenic. Xenobiotica 2008;34:973-82. [DOI: 10.1080/00498250400010898] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
564 Lee S, Buhler DR. Functional Properties of a Rainbow Trout CYP3A27 Expressed by Recombinant Baculovirus in Insect Cells. Drug Metab Dispos 2002;30:1406-12. [DOI: 10.1124/dmd.30.12.1406] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
565 Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008;327:288-99. [PMID: 18682571 DOI: 10.1124/jpet.108.141242] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
566 Johnson DR, Li CW, Chen LY, Ghosh JC, Chen JD. Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol Pharmacol 2006;69:99-108. [PMID: 16219912 DOI: 10.1124/mol.105.013375] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
567 von Moltke LL, Weemhoff JL, Perloff MD, Hesse LM, Harmatz JS, Roth-schechter BF, Greenblatt DJ. Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 2002;23:361-7. [DOI: 10.1002/bdd.329] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
568 Martínez-Jiménez CP, Gómez-Lechón MJ, Castell JV, Jover R. Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 2005;67:2088-101. [PMID: 15778453 DOI: 10.1124/mol.104.008169] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
569 Mouly S, Meune C, Bergmann JF. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Med. 2009;35:417-429. [PMID: 19132343 DOI: 10.1007/s00134-008-1384-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
570 Fu Y, Li M, Liu C, Qu JP, Zhu WJ, Xing HJ, Xu SW, Li S. Effect of atrazine and chlorpyrifos exposure on cytochrome P450 contents and enzyme activities in common carp gills. Ecotoxicol Environ Saf 2013;94:28-36. [PMID: 23702303 DOI: 10.1016/j.ecoenv.2013.04.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
571 Estève J, Blouin JM, Lalanne M, Azzi-Martin L, Dubus P, Bidet A, Harambat J, Llanas B, Moranvillier I, Bedel A, Moreau-Gaudry F, Richard E. Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1. Stem Cell Res 2019;38:101467. [PMID: 31151050 DOI: 10.1016/j.scr.2019.101467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
572 Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT; and the HOPS Investigators. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med 2013;28:1302-10. [PMID: 23605401 DOI: 10.1007/s11606-013-2449-6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 9.0] [Reference Citation Analysis]
573 Wang J, You W, Wang N, Zhou W, Ge Y, Ma Z, Tan H, Wang Y, Gao Y. Ophiopogonin D Increases SERCA2a Interaction with Phospholamban by Promoting CYP2J3 Upregulation. Oxid Med Cell Longev 2020;2020:8857906. [PMID: 33488937 DOI: 10.1155/2020/8857906] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
574 Baylon JL, Lenov IL, Sligar SG, Tajkhorshid E. Characterizing the membrane-bound state of cytochrome P450 3A4: structure, depth of insertion, and orientation. J Am Chem Soc 2013;135:8542-51. [PMID: 23697766 DOI: 10.1021/ja4003525] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 13.9] [Reference Citation Analysis]
575 Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir: . Journal of Acquired Immune Deficiency Syndromes 2000;24:129-36. [DOI: 10.1097/00042560-200006010-00007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
576 Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma JD. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit 2015;37:84-9. [PMID: 25004135 DOI: 10.1097/FTD.0000000000000116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
577 Crosby M, Riddick DS. Suppression of Hepatic CYP3A4 Expression and Activity by 3-Methylcholanthrene in Humanized PXR-CAR-CYP3A4/3A7 Mice. Drug Metab Dispos 2019;47:279-82. [PMID: 30573465 DOI: 10.1124/dmd.118.084509] [Reference Citation Analysis]
578 Petri N, Lennernäs H. In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. In: van de Waterbeemd H, Testa B, editors. Drug Bioavailability. Wiley; 2008. pp. 185-219. [DOI: 10.1002/9783527623860.ch9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
579 Kazemnejad S, Allameh A, Soleimani M, Gharehbaghian A, Mohammadi Y, Amirizadeh N, Esmaeili S. Functional Hepatocyte-Like Cells Derived from Human Bone Marrow Mesenchymal Stem Cells on a Novel 3-Dimensional Biocompatible Nanofibrous Scaffold. Int J Artif Organs 2008;31:500-7. [DOI: 10.1177/039139880803100605] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
580 Spencer EA, Key TJ, Appleby PN, van Gils CH, Olsen A, Tjønneland A, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Sánchez MJ, Bingham S, Khaw KT, Slimani N, Kaaks R, Riboli E. Prospective study of the association between grapefruit intake and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2009;20:803-9. [PMID: 19224379 DOI: 10.1007/s10552-009-9310-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
581 Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-forti G, Miglioli M, Biagi GL, Paolini M. The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management. American Journal of Gastroenterology 2003;98:1010-5. [DOI: 10.1111/j.1572-0241.2003.07427.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
582 Subhani S, Jamil K. Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. Biomedicine & Pharmacotherapy 2015;73:65-74. [DOI: 10.1016/j.biopha.2015.05.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
583 Dangi B, Davydova NY, Maldonado MA, Abbasi A, Vavilov NE, Zgoda VG, Davydov DR. Effects of alcohol-induced increase in CYP2E1 content in human liver microsomes on the activity and cooperativity of CYP3A4. Arch Biochem Biophys 2021;698:108677. [PMID: 33197431 DOI: 10.1016/j.abb.2020.108677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
584 Pondugula SR, Tong AA, Wu J, Cui J, Chen T. Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. Drug Metab Dispos 2010;38:1411-6. [PMID: 20538721 DOI: 10.1124/dmd.110.032128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
585 Fantoni M, Autore C, Borgo C. Drugs and Cardiotoxicity in HIV and AIDS. Annals of the New York Academy of Sciences 2006;946:179-99. [DOI: 10.1111/j.1749-6632.2001.tb03912.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
586 Davydov DR, Kumar S, Halpert JR. Allosteric mechanisms in P450eryF probed with 1-pyrenebutanol, a novel fluorescent substrate. Biochem Biophys Res Commun 2002;294:806-12. [PMID: 12061778 DOI: 10.1016/S0006-291X(02)00565-X] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
587 de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics 2013;14:1467-80. [PMID: 24024898 DOI: 10.2217/pgs.13.133] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
588 Samuels ER, Sevrioukova I. Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. Mol Pharm 2018;15:279-88. [PMID: 29232137 DOI: 10.1021/acs.molpharmaceut.7b00957] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
589 Gopalakrishnan Nair PM, Chung IM. Alteration in the expression of antioxidant and detoxification genes in Chironomus riparius exposed to zinc oxide nanoparticles. Comp Biochem Physiol B Biochem Mol Biol 2015;190:1-7. [PMID: 26278375 DOI: 10.1016/j.cbpb.2015.08.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
590 Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq P, Starkel P, Horsmans Y. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007;46:261-70. [PMID: 17328584 DOI: 10.2165/00003088-200746030-00006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
591 Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-66. [PMID: 12120277 DOI: 10.1038/nrd753] [Cited by in Crossref: 337] [Cited by in F6Publishing: 301] [Article Influence: 17.7] [Reference Citation Analysis]
592 Theodoropoulos C, Demers C, Delvin E, Ménard D, Gascon-Barré M. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol (Oxf) 2003;58:489-99. [PMID: 12641633 DOI: 10.1046/j.1365-2265.2003.01743.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
593 Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J 2019;4:e15. [PMID: 31595257 DOI: 10.1016/j.pbj.0000000000000015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
594 Clark CT. Psychotropic drug use in perinatal women with bipolar disorder. Seminars in Perinatology 2020;44:151230. [DOI: 10.1016/j.semperi.2020.151230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Dar SA, Gora AH, Bhat IA, Kumar S, Srivastava P, Muralidhar P, Gupta S. Studies of anthelminthic benzimidazole derivatives on cytochrome P450 1A (CYP1A) dependent detoxification mechanism in Labeo rohita. Aquaculture 2017;481:79-84. [DOI: 10.1016/j.aquaculture.2017.08.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
596 Zhang T, Dai H, Liu LA, Lewis DFV, Wei D. Classification Models for Predicting Cytochrome P450 Enzyme-Substrate Selectivity. Mol Inf 2012;31:53-62. [DOI: 10.1002/minf.201100052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
597 Sheridan RP, Mcmasters DR, Voigt JH, Wildey MJ. eCounterscreening: Using QSAR Predictions to Prioritize Testing for Off-Target Activities and Setting the Balance between Benefit and Risk. J Chem Inf Model 2015;55:231-8. [DOI: 10.1021/ci500666m] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
598 Beckwitt CH, Clark AM, Wheeler S, Taylor DL, Stolz DB, Griffith L, Wells A. Liver 'organ on a chip'. Exp Cell Res. 2018;363:15-25. [PMID: 29291400 DOI: 10.1016/j.yexcr.2017.12.023] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 22.5] [Reference Citation Analysis]
599 Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol 2012;52:932-9. [PMID: 21646440 DOI: 10.1177/0091270011407194] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
600 Samuelsson K, Pickup K, Sarda S, Swales JG, Morikawa Y, Schulz-utermoehl T, Hutchison M, Wilson ID. Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. Xenobiotica 2012;42:1128-37. [DOI: 10.3109/00498254.2012.689888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
601 Biggs JS, Wan J, Cutler NS, Hakkola J, Uusimäki P, Raunio H, Yost GS. Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells. Mol Pharmacol 2007;72:514-25. [PMID: 17548528 DOI: 10.1124/mol.106.033795] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
602 Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002;87:681-6. [PMID: 12237780 DOI: 10.1038/sj.bjc.6600494] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
603 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
604 Chen Y, Tang Y, Chen S, Nie D. Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol Ther 2009;8:1265-72. [PMID: 19746521 DOI: 10.4161/cbt.8.13.8696] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
605 Holmgren G, Sjögren A, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P, Ingelman-sundberg M, Andersson TB, Edsbagge J. Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes. Drug Metab Dispos 2014;42:1401-6. [DOI: 10.1124/dmd.114.059154] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
606 Schwartz JB. Race but Not Age Affects Erythromycin Breath Test Results in Older Hypertensive Men. The Journal of Clinical Pharmacology 2001;41:324-9. [DOI: 10.1177/00912700122010023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
607 Gibson G, El-sankary W, Plant NJ. Receptor-dependent regulation of the CYP3A4 gene. Toxicology 2002;181-182:199-202. [DOI: 10.1016/s0300-483x(02)00281-0] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
608 Estève J, Blouin JM, Lalanne M, Azzi-Martin L, Dubus P, Bidet A, Harambat J, Llanas B, Moranvillier I, Bedel A, Moreau-Gaudry F, Richard E. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology. Biochem Biophys Res Commun 2019;517:677-83. [PMID: 31402115 DOI: 10.1016/j.bbrc.2019.07.109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
609 Cui W, Shen X, Agbas E, Tompkins B, Cameron-Carter H, Staudinger JL. Phosphorylation Modulates the Coregulatory Protein Exchange of the Nuclear Receptor Pregnane X Receptor. J Pharmacol Exp Ther 2020;373:370-80. [PMID: 32205367 DOI: 10.1124/jpet.119.264762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
610 Ge X, Wang J, Liu J, Jiang J, Lin H, Wu J, Ouyang M, Tang X, Zheng M, Liao M, Deng Y. The catalytic activity of cytochrome P450 3A22 is critical for the metabolism of T-2 toxin in porcine reservoirs. Catalysis Communications 2010;12:71-5. [DOI: 10.1016/j.catcom.2010.08.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
611 Ferron PJ, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie 2020;179:266-74. [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
612 Roy K, Roy PP. QSAR of cytochrome inhibitors. Expert Opin Drug Metab Toxicol 2009;5:1245-66. [PMID: 19708826 DOI: 10.1517/17425250903158940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
613 Shen HW, Jiang XL, Gonzalez FJ, Yu AM. Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metab 2011;12:997-1006. [PMID: 22023319 DOI: 10.2174/138920011798062265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
614 Chen J, Liu J, Huang Y, Li R, Ma C, Zhang B, Wu F, Yu W, Zuo X, Liang Y, Wang Q. Insights into oral bioavailability enhancement of therapeutic herbal constituents by cytochrome P450 3A inhibition. Drug Metab Rev 2021;:1-17. [PMID: 33905669 DOI: 10.1080/03602532.2021.1917598] [Reference Citation Analysis]
615 Taneja G, Maity S, Jiang W, Moorthy B, Coarfa C, Ghose R. Transcriptomic profiling identifies novel mechanisms of transcriptional regulation of the cytochrome P450 (Cyp)3a11 gene. Sci Rep 2019;9:6663. [PMID: 31040347 DOI: 10.1038/s41598-019-43248-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
616 Nakayama A, Saitoh H, Oda M, Takada M, Aungst BJ. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. European Journal of Pharmaceutical Sciences 2000;11:317-24. [DOI: 10.1016/s0928-0987(00)00113-5] [Cited by in Crossref: 26] [Article Influence: 1.2] [Reference Citation Analysis]
617 Hisaka A, Kusama M, Ohno Y, Sugiyama Y, Suzuki H. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet 2009;48:653-66. [PMID: 19743887 DOI: 10.2165/11317220-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
618 Lewi DF, Bird MG, Jacobs MN. Human carcinogens: an evaluation study via the COMPACT and HazardExpert procedures. Hum Exp Toxicol 2002;21:115-22. [PMID: 12102536 DOI: 10.1191/0960327102ht233oa] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
619 Bonilla-valverde D, Ruiz-laguna J, Muñoz A, Ballesteros J, Lorenzo F, Gómez-ariza J, López-barea J. Evolution of biological effects of Aznalcóllar mining spill in the Algerian mouse (Mus spretus) using biochemical biomarkers. Toxicology 2004;197:122-37. [DOI: 10.1016/j.tox.2003.12.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
620 Sligar SG, Denisov IG. Understanding cooperativity in human p450 mediated drug-drug interactions. Drug Metab Rev 2007;39:567-79. [PMID: 17786639 DOI: 10.1080/03602530701498521] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
621 Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619:243-253. [PMID: 12573484 DOI: 10.1016/s0304-4165(02)00483-x] [Cited by in Crossref: 244] [Cited by in F6Publishing: 59] [Article Influence: 13.6] [Reference Citation Analysis]
622 Shimizu M, Uno T, Tamura HO, Kanazawa H, Murakami I, Sugawara K, Tateishi T. A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:275-81. [PMID: 17085083 DOI: 10.1016/j.jchromb.2006.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
623 Zhao M, Xiaofei L, Gang C, Wei L, Jing X, Gang H, Ruini C, Rui N, Wei S, Jian Y, Bingfang Y. DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes. Biochem Pharmacol 2012;84:701-11. [PMID: 22728071 DOI: 10.1016/j.bcp.2012.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
624 Zhang P, Lu G, Liu J, Yan Z, Wang Y. Toxicological responses of Carassius auratus induced by benzophenone-3 exposure and the association with alteration of gut microbiota. Sci Total Environ 2020;747:141255. [PMID: 32771788 DOI: 10.1016/j.scitotenv.2020.141255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
625 Steed H, Sawyer MB. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 2007;8:803-15. [PMID: 17638515 DOI: 10.2217/14622416.8.7.803] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
626 Zhou C, Tabb MM, Sadatrafiei A, Grün F, Blumberg B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos. 2004;32:1075-1082. [PMID: 15269186 DOI: 10.1124/dmd.104.000299] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
627 Auclair K, Polic V. Use of chemical auxiliaries to control p450 enzymes for predictable oxidations at unactivated C-h bonds of substrates. Adv Exp Med Biol 2015;851:209-28. [PMID: 26002737 DOI: 10.1007/978-3-319-16009-2_8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
628 Zhang G, Ou R, Li F, Wu J, Zheng L, Tong Y, Liu Y, Liu Z, Lu L. Regulation of drug-metabolizing enzymes and efflux transporters by Astragali radix decoction and its main bioactive compounds: Implication for clinical drug-drug interactions. J Ethnopharmacol 2016;180:104-13. [PMID: 26805467 DOI: 10.1016/j.jep.2016.01.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
629 Quesada-García A, Valdehita A, del Olmo I, Gómez MJ, Navas JM. Detection of effects caused by very low levels of contaminants in riverine sediments through a combination of chemical analysis, in vitro bioassays, and farmed fish as sentinel. Arch Environ Contam Toxicol 2015;68:663-77. [PMID: 25578768 DOI: 10.1007/s00244-014-0127-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
630 Haarhoff ZE, Kramer MA, Zvyaga TA, Zhang J, Bhutani P, Subramanian M, Rodrigues AD. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human. Xenobiotica 2017;47:470-8. [DOI: 10.1080/00498254.2016.1203042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
631 Zhou S, Chan E, Li X, Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005;1:3-13. [PMID: 18360537 DOI: 10.2147/tcrm.1.1.3.53600] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
632 Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW. Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther 2004;311:728-35. [PMID: 15282264 DOI: 10.1124/jpet.104.068908] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
633 Wei Z, Chen M, Zhang Y, Wang X, Jiang S, Wang Y, Wu X, Qin S, He L, Zhang L, Xing Q. No correlation of hsa-miR-148a with expression of PXR or CYP3A4 in human livers from Chinese Han population. PLoS One 2013;8:e59141. [PMID: 23527115 DOI: 10.1371/journal.pone.0059141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
634 Yoon MY, Campbell AP, Atkins WM. "Allosterism" in the elementary steps of the cytochrome P450 reaction cycle. Drug Metab Rev 2004;36:219-30. [PMID: 15237852 DOI: 10.1081/dmr-120033998] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
635 Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck J, Schweitzer A, Berthier S, Moenius T, Grassberger MA. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO. Drug Metab Dispos 2006;34:765-74. [DOI: 10.1124/dmd.105.007732] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
636 Wanwimolruk S, Wong K, Wanwimolruk P. Variable Inhibitory Effect of Different Brands of Commercial Herbal Supplements on Human Cytochrome P-450 CYP3A4. Drug Metabolism and Drug Interactions 2009;24. [DOI: 10.1515/dmdi.2009.24.1.17] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
637 Shi JG, Fraczkiewicz G, Williams WV, Yeleswaram S. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clin Pharmacol Ther 2015;97:177-85. [PMID: 25670523 DOI: 10.1002/cpt.30] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
638 Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Critical Reviews in Oncology/Hematology 2007;61:222-9. [DOI: 10.1016/j.critrevonc.2006.09.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
639 Justenhoven C. Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. Front Genet 2012;3:258. [PMID: 23226154 DOI: 10.3389/fgene.2012.00258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
640 Xie Y, Hao H, Wang H, Guo C, Kang A, Wang G. Reversing effects of lignans on CCl4-induced hepatic CYP450 down regulation by attenuating oxidative stress. J Ethnopharmacol. 2014;155:213-221. [PMID: 24910408 DOI: 10.1016/j.jep.2014.05.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
641 Brian Houston J, Kenworthy K, Galetin A. Typical and Atypical Enzyme Kinetics. In: Lee J, Scott Obach R, Fisher M, editors. Drug Metabolizing Enzymes. Informa Healthcare; 2003. pp. 211-54. [DOI: 10.1201/9781420028485.ch7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
642 Bořek-Dohalská L, Hodek P, Hudeček J, Stiborová M. Experimental approaches to evaluate activities of cytochromes P450 3A. Interdiscip Toxicol 2008;1:155-9. [PMID: 21218106 DOI: 10.2478/v10102-010-0032-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
643 Cárcamo JG, Aguilar MN, Barrientos CA, Carreño CF, Quezada CA, Bustos C, Manríquez RA, Avendaño-herrera R, Yañez AJ. Effect of emamectin benzoate on transcriptional expression of cytochromes P450 and the multidrug transporters (Pgp and MRP1) in rainbow trout (Oncorhynchus mykiss) and the sea lice Caligus rogercresseyi. Aquaculture 2011;321:207-15. [DOI: 10.1016/j.aquaculture.2011.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
644 Tomalik-Scharte D, Suleiman AA, Frechen S, Kraus D, Kerkweg U, Rokitta D, Di Gion P, Queckenberg C, Fuhr U. Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. J Clin Pharmacol 2014;54:1162-9. [PMID: 24782075 DOI: 10.1002/jcph.318] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
645 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Boston: Springer US; 2005. pp. 377-530. [DOI: 10.1007/0-387-27447-2_10] [Cited by in Crossref: 176] [Cited by in F6Publishing: 96] [Reference Citation Analysis]
646 Roberts AG, Atkins WM. Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4. Arch Biochem Biophys 2007;463:89-101. [PMID: 17459328 DOI: 10.1016/j.abb.2007.03.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
647 Jamwal R, de la Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. Mol Pharm 2018;15:2621-32. [PMID: 29792708 DOI: 10.1021/acs.molpharmaceut.8b00159] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
648 Polic V, Auclair K. Allosteric Activation of Cytochrome P450 3A4 via Progesterone Bioconjugation. Bioconjug Chem 2017;28:885-9. [PMID: 28339191 DOI: 10.1021/acs.bioconjchem.6b00604] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
649 Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 2007;35:2095-101. [PMID: 17724065 DOI: 10.1124/dmd.107.016733] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
650 Sanchez E, Rodríguez A, Grau JH, Lötters S, Künzel S, Saporito RA, Ringler E, Schulz S, Wollenberg Valero KC, Vences M. Transcriptomic Signatures of Experimental Alkaloid Consumption in a Poison Frog. Genes (Basel) 2019;10:E733. [PMID: 31546679 DOI: 10.3390/genes10100733] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
651 Abass KM. From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan. Pesticide Biochemistry and Physiology 2013;107:258-65. [DOI: 10.1016/j.pestbp.2013.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
652 Mantri M, Zhang Z, Mcdonough MA, Schofield CJ. Autocatalysed oxidative modifications to 2-oxoglutarate dependent oxygenases: Oxidative modifications to 2OG oxygenases. FEBS Journal 2012;279:1563-75. [DOI: 10.1111/j.1742-4658.2012.08496.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
653 Li H, Wang YG, Ma ZC, Yun-Hang G, Ling S, Teng-Fei C, Guang-Ping Z, Gao Y. A high-throughput cell-based gaussia luciferase reporter assay for measurement of CYP1A1, CYP2B6, and CYP3A4 induction. Xenobiotica 2021;51:752-63. [PMID: 33896369 DOI: 10.1080/00498254.2021.1918800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Chen R, Jiang J, Hu Z, Ye W, Yuan Q, Li M, Wen J, Deng Y. Coordinated Transcriptional Regulation of Cytochrome P450 3As by Nuclear Transcription Factor Y and Specificity Protein 1. Mol Pharmacol 2019;95:507-18. [PMID: 30782853 DOI: 10.1124/mol.118.114439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Ononye SN, Shi W, Wali VB, Aktas B, Jiang T, Hatzis C, Pusztai L. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets. Breast Cancer Res Treat 2014;148:477-88. [PMID: 25395317 DOI: 10.1007/s10549-014-3194-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
656 Sadeghi SJ, Tsotsou GE, Fairhead M, Meharenna YT, Gilardi G. Rational Design of P450 Enzymes for Biotechnology. In: De Cuyper M, Bulte JWM, editors. Physics and Chemistry Basis of Biotechnology. Dordrecht: Springer Netherlands; 2002. pp. 71-104. [DOI: 10.1007/0-306-46891-3_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
657 Chougnet A, Stoessel C, Woggon WD. Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). Bioorg Med Chem Lett 2003;13:3643-5. [PMID: 14552748 DOI: 10.1016/j.bmcl.2003.08.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
658 Dashti-Khavidaki S, Saidi R, Lu H. Current status of glucocorticoid usage in solid organ transplantation. World J Transplant 2021; 11(11): 443-465 [DOI: 10.5500/wjt.v11.i11.443] [Reference Citation Analysis]
659 Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P, Salehi M. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd011841] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
660 Huang M, Xu X, Yang H, Liu S. Electrochemically-driven and dynamic enhancement of drug metabolism via cytochrome P450 microsomes on colloidal gold/graphene nanocomposites. RSC Adv 2012;2:12844. [DOI: 10.1039/c2ra22014h] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
661 Noe S, Jaeger H, Heldwein S. Adrenal insufficiency due to ritonavir-triamcinolone drug-drug interaction without preceding Cushing's syndrome. Int J STD AIDS 2018;29:1136-9. [PMID: 29749880 DOI: 10.1177/0956462418768689] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
662 Moreno I, Quiñones L, Catalán J, Miranda C, Roco A, Sasso J, Tamayo E, Cáceres D, Tchernitchin AN, Gaete L, Saavedra I. Influencia de polimorfismos genéticos de CYP3A4/5 en la farmacocinética de levonorgestrel: estudio piloto. biomedica 2012;32. [DOI: 10.7705/biomedica.v32i4.789] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
663 Lewis DF, Ogg MS, Goldfarb PS, Gibson GG. Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J Steroid Biochem Mol Biol 2002;82:195-9. [PMID: 12477485 DOI: 10.1016/s0960-0760(02)00158-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
664 Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071-1088. [PMID: 14531721 DOI: 10.2165/00003088-200342130-00001] [Cited by in Crossref: 152] [Cited by in F6Publishing: 111] [Article Influence: 8.9] [Reference Citation Analysis]
665 Zhang W, Mcintyre C, Forbes H, Gaafar R, Kohail H, Beck JT, Plestina S, Bertran E, Riehl T. Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy. Clinical Pharmacology in Drug Development 2019;8:837-43. [DOI: 10.1002/cpdd.643] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
666 Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006;20:2613-29. [PMID: 16543404 DOI: 10.1210/me.2006-0007] [Cited by in Crossref: 283] [Cited by in F6Publishing: 273] [Article Influence: 18.9] [Reference Citation Analysis]
667 Arora V, Hannah TL, Iversen PL, Brand RM. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res 2002;19:1465-70. [PMID: 12425463 DOI: 10.1023/a:1020448430919] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
668 Ranadive I, Patel S, Mhaske A, Uggini GK, Desai I, Balakrishnan S. Evaluation of multikinase inhibitor LDN193189 induced hepatotoxicity in teleost fish Poecilia latipinna. Drug Chem Toxicol 2019;42:565-76. [PMID: 29498548 DOI: 10.1080/01480545.2018.1441865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
669 Orbach SM, Ehrich MF, Rajagopalan P. High-throughput toxicity testing of chemicals and mixtures in organotypic multi-cellular cultures of primary human hepatic cells. Toxicol In Vitro 2018;51:83-94. [PMID: 29751030 DOI: 10.1016/j.tiv.2018.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
670 Nakada N, Kawamura A, Kamimura H, Sato K, Kazuki Y, Kakuni M, Ohbuchi M, Kato K, Tateno C, Oshimura M, Usui T. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans: Nefazodone Metabolism in Humanized Cyp3a KO Chimeric Mice. Biopharm Drug Dispos 2016;37:3-14. [DOI: 10.1002/bdd.1990] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
671 Moore A, Pinkerton R. Vincristine: Can its therapeutic index be enhanced? Pediatr Blood Cancer 2009;53:1180-7. [DOI: 10.1002/pbc.22161] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
672 Yan D, Yang Y, Uchida S, Misaka S, Luo J, Takeuchi K, Inui N, Yamada S, Ohashi K, Watanabe H. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. Naunyn-Schmied Arch Pharmacol 2008;377:629-36. [DOI: 10.1007/s00210-007-0217-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
673 Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica. 2002;32:451-478. [PMID: 12160480 DOI: 10.1080/00498250210124147] [Cited by in Crossref: 160] [Cited by in F6Publishing: 133] [Article Influence: 8.4] [Reference Citation Analysis]
674 Zhang Y, Li Y, Li Q. Inhibition of cytochrome P450 3A in rat liver by the Diorganotin (IV) compound di-n-Butyl-di-(4-chlorobenzo-hydroxamato)tin (IV) and Its Probable Mechanism. Molecules 2012;17:10994-1009. [PMID: 22971584 DOI: 10.3390/molecules170910994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
675 Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9:315-344. [PMID: 18386306 DOI: 10.1111/j.1526-4637.2006.00289.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
676 Goodwin B, Moore JT. CAR: detailing new models. Trends in Pharmacological Sciences 2004;25:437-41. [DOI: 10.1016/j.tips.2004.06.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
677 Dilger K, Alberer M, Busch A, Enninger A, Behrens R, Koletzko S, Stern M, Beckmann C, Gleiter CH. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther 2006;23:387-96. [DOI: 10.1111/j.1365-2036.2006.02771.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
678 Chen Y, Tang Y, Robbins GT, Nie D. Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 2010;334:999-1008. [PMID: 20504912 DOI: 10.1124/jpet.110.168294] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
679 Shaik S, Milko P, Schyman P, Usharani D, Chen H. Trends in Aromatic Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes: A Valence Bond Modeling. J Chem Theory Comput 2011;7:327-39. [DOI: 10.1021/ct100554g] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
680 Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metabolism Reviews 2002;34:17-35. [DOI: 10.1081/dmr-120001387] [Cited by in Crossref: 110] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
681 Zhu J, Tian X, Shehu AI, McMahon DK, Ma X. ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics. J Pharmacol Exp Ther 2020;374:38-43. [PMID: 32303561 DOI: 10.1124/jpet.119.264424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
682 Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42:835-45. [PMID: 12162466 DOI: 10.1177/009127002401102731] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
683 Cui H, Gu X, Chen J, Xie Y, Ke S, Wu J, Golovko A, Morpurgo B, Yan C, Phillips TD, Xie W, Luo J, Zhou Z, Tian Y. Pregnane X receptor regulates the AhR/Cyp1A1 pathway and protects liver cells from benzo-[α]-pyrene-induced DNA damage. Toxicol Lett 2017;275:67-76. [PMID: 28428138 DOI: 10.1016/j.toxlet.2017.03.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]